[ { "id": 83, "name": "Science Exchange", "slug": "science-exchange", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0db3228fbd884724c2ad75aeac20b60376478518.png", "website": "https://www.scienceexchange.com/", "all_locations": "Palo Alto, CA, USA; Remote", "long_description": "Science Exchange powers R&D outsourcing for the world’s top life sciences companies. Our marketplace gives scientists access to the innovation and research they need and our platform fully automates R&D outsourcing from source to pay so scientists can focus on what they love—science.", "one_liner": "Powering scientific outsourcing", "team_size": 50, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare Services", "launched_at": 1326789132, "tags": [ "SaaS", "Health Tech", "Biotech", "Enterprise" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2011", "status": "Acquired", "industries": [ "Healthcare", "Healthcare Services" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/science-exchange", "api": "https://yc-oss.github.io/api/batches/summer-2011/science-exchange.json" }, { "id": 445, "name": "Benchling", "slug": "benchling", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/56dfbb621883fb62890bd66d7bd967984b974c12.png", "website": "http://benchling.com", "all_locations": "San Francisco, CA, USA", "long_description": "Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, the materials we wear, and the household goods that we rely on every day. Biotech R&D is radically transforming our world, but to move at the new speed of science, scientists need better technology.\r\n\r\nBenchling’s mission is to unlock the power of biotechnology. The world’s biotech leaders and innovators use our R&D Cloud to power the development of breakthrough products and accelerate time to milestone and market.", "one_liner": "Unlocking the power of biotech with modern software for modern science", "team_size": 750, "industry": "B2B", "subindustry": "B2B", "launched_at": 1336096997, "tags": [ "SaaS", "B2B", "Biotech" ], "tags_highlighted": [], "top_company": true, "isHiring": false, "nonprofit": false, "batch": "Summer 2012", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": true, "url": "https://www.ycombinator.com/companies/benchling", "api": "https://yc-oss.github.io/api/batches/summer-2012/benchling.json" }, { "id": 647, "name": "Immunity Project", "slug": "immunity-project", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://immunityproject.org", "all_locations": "San Francisco, CA, USA", "long_description": "We're developing a free vaccine to cure HIV and AIDs. Immunity Project is a non-profit initiative dedicated to developing an HIV vaccine. We hacked the HIV life cycle to develop a vaccine that gives you the same power as HIV controllers. With success in our clinical trials, our goal is to give our vaccine away to the world for free.", "one_liner": "The free HIV vaccine.", "team_size": 11, "industry": "Unspecified", "subindustry": "Unspecified", "launched_at": 1389695796, "tags": [ "Health Tech", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": true, "batch": "Winter 2014", "status": "Active", "industries": [ "Unspecified" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/immunity-project", "api": "https://yc-oss.github.io/api/batches/winter-2014/immunity-project.json" }, { "id": 734, "name": "One Codex", "slug": "one-codex", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5eedcdf8d152fac7180dc5402647f58cd164448a.png", "website": "https://www.onecodex.com", "all_locations": "Boston, MA, USA; San Francisco, CA, USA", "long_description": "One Codex is a data platform for applied microbial genomics, enabling new and valuable applications in clinical diagnostics, food safety, and biosecurity. Acquired by Invitae (NVTA) in February 2021. Spun out as an independent company in September 2022.", "one_liner": "Data platform for metagenomics and the microbiome.", "team_size": 16, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare IT", "launched_at": 1401532729, "tags": [ "Biotech", "Diagnostics", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2014", "status": "Acquired", "industries": [ "Healthcare", "Healthcare IT" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/one-codex", "api": "https://yc-oss.github.io/api/batches/summer-2014/one-codex.json" }, { "id": 739, "name": "Notable Labs", "slug": "notable-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c2bf47d120c3bdde2a9ad11d9f05f1c08a72ca0e.png", "website": "http://notablelabs.com", "all_locations": "Foster City, CA, USA", "long_description": "Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships.\r\n\r\nhttps://www.notablelabs.com/careers", "one_liner": "Personalized drug discovery for blood cancer.", "team_size": 40, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1407578442, "tags": [ "Biotech", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": true, "isHiring": true, "nonprofit": false, "batch": "Winter 2015", "status": "Public", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": true, "app_answers": false, "question_answers": false, "url": "https://www.ycombinator.com/companies/notable-labs", "api": "https://yc-oss.github.io/api/batches/winter-2015/notable-labs.json" }, { "id": 747, "name": "20n", "slug": "20n", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://20n.com", "all_locations": "San Francisco, CA, USA", "long_description": "The next decade is going to see a biotech revolution fueled by three technologies: ability to read DNA (sequencing), ability to write DNA (synthesis), and computational systems that predict what DNA to read and write. With sequencing and synthesis being mainstream now [1], 20n provides the computational systems that predict DNA design for novel industrial biotech and health applications.\n\nAt 20n, we are taking a fresh look at turning biological data into information. We approach it as a big data learning problem, and bring to bear techniques from machine learning, distributed systems, AI planning, program synthesis, data mining, and natural language processing. With the support of DARPA [2], we are building a team of computer scientists, and bioengineers to look at biology in fundamentally new ways.\n\nOur current customers include industrial biotech firms that are leading the charge in transitioning us from traditional unsustainable means of manufacturing to sustainable biological processes leading to advanced fuels, materials, therapeutics, and flavors and fragrances. 20n’s technology helps them enter markets previously thought inaccessible for biology.\n\n[1] Sequencing DNA costs $4k/genome (http://www.genome.gov/sequencingcosts/) and is expected to go down to $1k/genome. Synthesizing DNA is at 20cents/bp, and is expected to go down to 0.1cents/bp.\n[2] DARPA in the past supported work that led to the internet, stealth planes, GPS, and even Douglas Engelbart’s mother-of-all-demos.", "one_liner": "Using AI to predict biochemistry for manufacturing and therapeutics", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1416218423, "tags": [ "Artificial Intelligence", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2015", "status": "Inactive", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/20n", "api": "https://yc-oss.github.io/api/batches/winter-2015/20n.json" }, { "id": 756, "name": "Numerion Labs", "slug": "numerion-labs", "former_names": [ "Atomwise" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c3b218096497a702becc32895ca1b21c4cae78bd.png", "website": "https://www.numerionlabs.ai", "all_locations": "San Francisco, CA, USA", "long_description": "Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge machine learning algorithms. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.", "one_liner": "Artificial intelligence for drug discovery.", "team_size": 67, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1416219336, "tags": [ "AI-powered Drug Discovery", "Deep Learning", "Biotech", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2015", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/numerion-labs", "api": "https://yc-oss.github.io/api/batches/winter-2015/numerion-labs.json" }, { "id": 835, "name": "Transcriptic", "slug": "transcriptic", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/04d24967c3e4ff77621b1783e6234eaa80f83fa2.png", "website": "http://transcriptic.com", "all_locations": "Menlo Park, CA, USA", "long_description": "Founded in 2012, Transcriptic has developed the first robotic cloud lab platform for on-demand life science research. It’s powered by the Transcriptic Common Lab Environment (TCLE) a scalable, digital infrastructure that integrates laboratory processes, instruments and IoT technologies into a single user interface. Researchers can carry out scalable, reproducible and rapid experimentation from anywhere in the world. \r\n\r\nTop ten pharmaceutical companies, as well as emerging biotech companies, are using the platform to gain more reproducibility and flexibility in the design and control of their experiments. By leveraging cloud-based technologies, users can access the power of a fully automated laboratory – whether in their own labs through an on-premise deployment of TCLE or through Transcriptic’s Bioassays services – all through a simple web-based interface. \r\n\r\nTranscriptic is transforming drug discovery and synthetic biology research by helping scientists focus on accelerating discoveries instead of labor-intensive bench work.", "one_liner": "The robotic cloud laboratory for the life sciences.", "team_size": 13, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare Services", "launched_at": 1416311312, "tags": [ "Robotics", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2015", "status": "Inactive", "industries": [ "Healthcare", "Healthcare Services" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/transcriptic", "api": "https://yc-oss.github.io/api/batches/winter-2015/transcriptic.json" }, { "id": 857, "name": "Shasqi", "slug": "shasqi", "former_names": [ "Shasqi", "Tambo" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ffc67fc2138abb0d2b24dd42fa7b056c024ad80a.png", "website": "", "all_locations": "San Francisco, CA, USA; Remote", "long_description": "Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ platform. Our technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two 'click', a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds.", "one_liner": "Targeting Cancer with Click Chemistry", "team_size": 28, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1421189619, "tags": [ "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2015", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/shasqi", "api": "https://yc-oss.github.io/api/batches/winter-2015/shasqi.json" }, { "id": 962, "name": "Cofactor Genomics", "slug": "cofactor-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0138772cf18d9846bdac1578f7edd2288e7e4142.png", "website": "http://cofactorgenomics.com", "all_locations": "St. Louis, MO, USA", "long_description": "Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes.\r\n\r\nLed by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. \r\n\r\nThe team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. \r\n\r\nAfter a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. \r\n\r\nCurrent investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).", "one_liner": "Cofactor closes the precision medicine gap with predictive diagnostics", "team_size": 13, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1433394319, "tags": [ "Medical Devices", "Biotech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2015", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/cofactor-genomics", "api": "https://yc-oss.github.io/api/batches/summer-2015/cofactor-genomics.json" }, { "id": 1000, "name": "Loop Genomics", "slug": "loop-genomics", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.loopgenomics.com/", "all_locations": "San Jose, CA, USA", "long_description": "Loop Genomics provides long-read sequencing solutions across a diverse set of research and clinical applications. Our platform for long-read DNA sequencing transforms short-read DNA sequencers into long-read sequencing machines. ", "one_liner": "Novel long-read DNA sequencing technology", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1447280416, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Acquired", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/loop-genomics", "api": "https://yc-oss.github.io/api/batches/winter-2016/loop-genomics.json" }, { "id": 1023, "name": "Unima", "slug": "unima", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6c2c011e4d98e07f268e9d5fe993f2508a4a51e7.png", "website": "http://www.unimadx.com", "all_locations": "Zapopan, Jal., Mexico", "long_description": "Unima developed a fast and low-cost diagnostic and real-time disease surveillance that allows anyone to diagnose a disease directly where the patient is, without using lab equipment, with results in 15 minutes and at a very low cost.", "one_liner": "Fast and low-cost diagnostics for real time disease surveillance", "team_size": 26, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1447312816, "tags": [ "Health Tech", "Biotech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Mexico", "Latin America" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/unima", "api": "https://yc-oss.github.io/api/batches/winter-2016/unima.json" }, { "id": 1030, "name": "Opentrons", "slug": "opentrons", "former_names": [ "OpenTrons" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/218a1e71ef58cf5c6cbd797a5c9a25f5b4525037.png", "website": "http://opentrons.com", "all_locations": "New York, NY, USA", "long_description": "Today, biologists spend too much time pipetting by hand. We think biologists should have robots to do pipetting for them. People doing science should be free of tedious benchwork and repetitive stress injuries. They should be able to spend their time designing experiments and analyzing data.\r\n\r\nThat's why we started Opentrons.\r\n\r\nWe make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other's results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century’s most important questions.", "one_liner": "We make robots for biologists. ", "team_size": 300, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1447527916, "tags": [ "Robotics", "Synthetic Biology", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/opentrons", "api": "https://yc-oss.github.io/api/batches/winter-2016/opentrons.json" }, { "id": 1053, "name": "HistoWiz", "slug": "histowiz", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://histowiz.com", "all_locations": "Brooklyn, NY, USA", "long_description": "HistoWiz is an innovative company dedicated to accelerating pathology-based research.\r\n\r\nHistoWiz provides fast, global access to digital whole-slide images, online collaboration tools, low-cost data management, and experimental pathology expertise. The web-based platform accelerates information exchange among medical scientists and research pathologists. HistoWiz's mission is to fight cancer cooperatively instead of individually by connecting scientists and pathologists for online collaboration.\r\n\r\nThe HistoWiz advantage\r\nWe help your lab minimize the cost of research and maximize research productivity by providing the most efficient service for scientists to analyze experimental pathology specimens. We believe that scientists should spend their time on results interpretation rather than repetitive tissue cutting.\r\n\r\nHow does it work?\r\nHistoWiz accepts formalin-fixed specimens by mail for tissue processing services. To expedite delivery of results and to facilitate global collaboration, HistoWiz offers whole-slide imaging and pathology services, allowing researchers to remotely and instantly view high-magnification images of their specimens via a secure, cloud-based “virtual microscope” on any computer or mobile device without downloading any software or gigabyte-sized files.", "one_liner": "Accelerating Histopathology for Cancer Research ", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare Services", "launched_at": 1447653916, "tags": [ "Biotech", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Active", "industries": [ "Healthcare", "Healthcare Services" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/histowiz", "api": "https://yc-oss.github.io/api/batches/winter-2016/histowiz.json" }, { "id": 1251, "name": "Synvivia", "slug": "synvivia", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4447def03db194c618a13840346e31a2394d316e.png", "website": "https://www.synvivia.com", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "Synvivia applies chemical control over cell behavior. This allows us to optimize biomanufacturing of high-value biopharmaceutical products.", "one_liner": "Synvivia applies chemical control over cell behavior", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1672775025, "tags": [ "Artificial Intelligence", "Synthetic Biology", "Biotech", "Manufacturing", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2016", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/synvivia", "api": "https://yc-oss.github.io/api/batches/summer-2016/synvivia.json" }, { "id": 1491, "name": "InnaMed", "slug": "innamed", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5a5f04ad2b7ba3169c85be1ac62f4a434b27d75d.png", "website": "http://www.InnaMed.com", "all_locations": "San Francisco, CA, USA; Philadelphia, PA, USA", "long_description": "InnaMed's HomeLab device and software take the hassle out of blood testing and let you access precision medical care from the comfort and privacy of your home. Healthcare providers and researchers can now receive timely clinical reports that they are accustomed to interpreting directly to their EMR, LIMS or EDC system. Trend identification and pattern matching software can guide decision making in the prescription and dosing of therapy and deep integration with the healthcare system and telehealth services allows for data driven care while also ensuring human connection.\r\n\r\n\r\n", "one_liner": "At-home blood testing: measure + analyze + enhance.", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1478225435, "tags": [ "Biotech", "Digital Health", "Telemedicine" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/innamed", "api": "https://yc-oss.github.io/api/batches/winter-2017/innamed.json" }, { "id": 1560, "name": "Helix Nanotechnologies", "slug": "helix-nanotechnologies", "former_names": [ "Helix Nanotechnologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f05a634de42c2c96484608b63b33b99fd27aa56e.png", "website": "http://helixnano.com", "all_locations": "Boston, MA, USA; Cambridge, MA, USA", "long_description": "Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button.\r\n\r\nBy focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity.\r\n\r\nRigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas.\r\n\r\nWe've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.", "one_liner": "Next-generation mRNA platform to solve cancer, COVID and climate.", "team_size": 22, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1482443417, "tags": [ "Artificial Intelligence", "Biotech", "Genomics", "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/helix-nanotechnologies", "api": "https://yc-oss.github.io/api/batches/winter-2017/helix-nanotechnologies.json" }, { "id": 1581, "name": "Sigma Genetics", "slug": "sigma-genetics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3d163f0758d535d9b800f2a88bdefffc73c5bbe2.png", "website": "http://www.sigmagenetics.com", "all_locations": "Seattle, WA, USA", "long_description": "Sigma Genetics develops devices that can deliver DNA, RNA, and other charged molecules into cells by using magnetic fields. When compared to conventional electroporation, this technique has several key advantages, which include: the absence of arcing, the ability to scale, and the benefit of being non-invasive for in vivo applications. This platform technology can be applied to a wide range of applications- cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetics.", "one_liner": "Sigma Genetics is a biotechnology company that is building…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1492902064, "tags": [ "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/sigma-genetics", "api": "https://yc-oss.github.io/api/batches/winter-2017/sigma-genetics.json" }, { "id": 1721, "name": "Lucy Goods, Inc", "slug": "lucy-goods-inc", "former_names": [ "Lucy", "Lucy Nicotine" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6fa905ed0111248b2a03722c5ba79f0b395dae83.png", "website": "https://lucy.co/", "all_locations": "Los Angeles, CA, USA", "long_description": "If it isn’t bad enough that smokers don’t realize the scientific facts about nicotine, most non-tobacco nicotine products are poorly designed and unappealing to use. The leading gum is sold like a pharmaceutical drug, with flavoring and packaging to match. Vapes provide a cumbersome, over-the-top experience — with use as tightly restricted as cigarette smoking itself, but more juvenile, conspicuous, and highly addictive. People want, and deserve, a better way.\r\n\r\nTherefore, we want to deliver nicotine users a superior experience, and at the same time give them a way to transition out of feeling dependent. In a better society, people wouldn’t carry around the sensation that they’re stuck with an involuntary habit. Our mission isn’t to encourage nicotine use among people who haven’t started. Unlike certain vapes or other products, ours isn’t the sort coveted by underage users on social media. Our mission is to alleviate the harm related to tobacco — first and foremost, by switching people away from the most harmful products.\r\n\r\nSo, at Lucy, we take an evidence based view of nicotine. Nicotine’s pleasurable properties make it an inevitable part of modern society. Therefore, minimizing harm in all nicotine products is key, in addition to giving people products and strategies for cessation. We feel that, as 1,300 people are dying of tobacco related illnesses every day in the US, the most important and immediate step toward a better society is giving nicotine consumers products they enjoy using that will cause less harm.\r\n\r\nOur first product is designed to appeal to smokers and encourage them to switch. And, looking ahead, we hope to secure approval in the future as a clinically proven smoking cessation aid, while continuing to participate in the FDA’s public hearings around how NRTs are best regulated. Our goals are simple: because harm reduction is a better strategy around nicotine delivery than abstinence or prohibition, we want to help improve public health — and reduce its costs — through a superior pure nicotine product.", "one_liner": "Lucy’s mission is to reduce tobacco-related harm to zero. We provide…", "team_size": 7, "industry": "Consumer", "subindustry": "Consumer -> Food and Beverage", "launched_at": 1507160421, "tags": [ "3D Printed Foods", "Biotech", "E-commerce" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Active", "industries": [ "Consumer", "Food and Beverage" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/lucy-goods-inc", "api": "https://yc-oss.github.io/api/batches/winter-2018/lucy-goods-inc.json" }, { "id": 1735, "name": "Ovipost", "slug": "ovipost", "former_names": [ "Eclosion Technologies", "Eclosion" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e02035f8a52b75f92fad791bafe6e88fb705655d.png", "website": "https://ovipost.com", "all_locations": "LaBelle, FL, USA", "long_description": "Ovipost builds automated insect farms. Insects are the most efficient way to convert abundant, cheap byproducts into nutritionally dense protein. Today live insects are a $175m industry in the US, but the future of the industry is leveraging their excellent amino acid profiles and superior digestibility to replace fishmeal ($9.5B industry) and other expensive proteins in animal feeds. Led by co-founders Trina Chiasson (sold Infoactive to Tableau) and Teq Sassmannshaus (biotech hardware engineer), the Ovipost team has deep experience in hardware, software, and biology. ", "one_liner": "Automated insect farming", "team_size": 20, "industry": "Industrials", "subindustry": "Industrials -> Agriculture", "launched_at": 1509562874, "tags": [ "Biotech", "Climate", "Food Tech", "Agriculture", "ClimateTech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Inactive", "industries": [ "Industrials", "Agriculture" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/ovipost", "api": "https://yc-oss.github.io/api/batches/winter-2018/ovipost.json" }, { "id": 1757, "name": "Avro Life Science", "slug": "avro-life-science", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5ac9275384f9ff51e1062f157268e402e8ef1354.png", "website": "http://avrolifesci.com", "all_locations": "Waterloo, ON, Canada", "long_description": "", "one_liner": "Skin patches for generic drug delivery. ", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1509599008, "tags": [ "Biotech", "Drug Delivery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "Canada", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/avro-life-science", "api": "https://yc-oss.github.io/api/batches/winter-2018/avro-life-science.json" }, { "id": 1775, "name": "Reverie Labs", "slug": "reverie-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c167c3874ed6d5b52b8c339d61851123a4540f2c.png", "website": "http://www.reverielabs.com", "all_locations": "Cambridge, MA, USA", "long_description": "Reverie Labs is engineering next-generation, brain-penetrant cancer therapies.\r\n", "one_liner": " Engineering next-generation, brain-penetrant cancer therapies.", "team_size": 29, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1509678248, "tags": [ "AI-powered Drug Discovery", "Machine Learning", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/reverie-labs", "api": "https://yc-oss.github.io/api/batches/winter-2018/reverie-labs.json" }, { "id": 1856, "name": "Culture Biosciences", "slug": "culture-biosciences", "former_names": [ "Culture Robotics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ac962091728b8d8d331a854791fa1b892cb9f93f.png", "website": "https://culturebiosciences.com", "all_locations": "South San Francisco, CA, USA", "long_description": "Culture Biosciences grows cells for biotech companies. Our customers genetically modify organisms to produce new therapeutics, materials, fuels and foods. We help them quickly run experiments and develop manufacturing processes so they can get their products to market faster. We've built proprietary software and automation systems to make operating our bioreactors more efficient than existing systems. We also provide customers with new software tools that help them analyze and contextualize their data. We are currently serving a number of biotech customers and scaling out our infrastructure.\r\n", "one_liner": "We grow cells for biotech companies.", "team_size": 40, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1511233372, "tags": [ "Cellular Agriculture", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/culture-biosciences", "api": "https://yc-oss.github.io/api/batches/winter-2018/culture-biosciences.json" }, { "id": 1892, "name": "C16 Biosciences", "slug": "c16-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0c1ec14e5944503b574c2783312bcb19bad730fc.png", "website": "https://www.c16bio.com/", "all_locations": "New York, NY, USA", "long_description": "C16 Biosciences is decarbonizing consumer products supply chains by producing next-generation ingredients. The company's biomanufacturing platform produces better performing, more sustainable alternatives to oils and fats, and their first product is an alternative to palm oil. The company owns and operates Palmless™ alternative fats and oils.", "one_liner": "Next-gen ingredients to decarbonize consumer products, starting w/…", "team_size": 35, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1524539156, "tags": [ "Biotech", "Sustainability", "Climate" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/c16-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2018/c16-biosciences.json" }, { "id": 1916, "name": "Data Driven Bioscience", "slug": "data-driven-bioscience", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://datadrivenbioscience.com", "all_locations": "Durham, NC, USA", "long_description": "", "one_liner": "Cancer Diagnosis 10X faster, 10X cheaper", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1524711770, "tags": [ "Artificial Intelligence", "Biotech", "Healthcare" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": true, "question_answers": false, "url": "https://www.ycombinator.com/companies/data-driven-bioscience", "api": "https://yc-oss.github.io/api/batches/summer-2018/data-driven-bioscience.json" }, { "id": 1931, "name": "Hepatx", "slug": "hepatx", "former_names": [ "Hepatx Corporation" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/de67131e3a59da3affe582ccd6f671eb18fb38f2.png", "website": "http://www.hepatx.com", "all_locations": "Palo Alto, CA, USA", "long_description": "Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.", "one_liner": "Replacing organ transplant with an infusion", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1524801868, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/hepatx", "api": "https://yc-oss.github.io/api/batches/summer-2018/hepatx.json" }, { "id": 1932, "name": "Radix Labs", "slug": "radix-labs", "former_names": [ "Phloem biotech" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0cac41291118dec8729ffc4b179a57d24f1c93ac.png", "website": "http://radix.bio", "all_locations": "Cambridge, MA, USA", "long_description": "", "one_liner": "Operating systems for biology labs", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1524873814, "tags": [ "IoT", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/radix-labs", "api": "https://yc-oss.github.io/api/batches/summer-2018/radix-labs.json" }, { "id": 1964, "name": "CB Therapeutics", "slug": "cb-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/95cebc7f272bba7c432325c1ec6e9b828643bcb5.png", "website": "http://www.cbthera.com", "all_locations": "San Diego, CA, USA", "long_description": "CB Therapeutics engineers microbes to produce high-value ingredients for medicines, supplements, and other wellness products through sustainable biomanufacturing. \r\n", "one_liner": "Fermentation-derived natural products to solve health problems ", "team_size": 18, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1525302481, "tags": [ "Cellular Agriculture", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/cb-therapeutics", "api": "https://yc-oss.github.io/api/batches/summer-2018/cb-therapeutics.json" }, { "id": 1967, "name": "Mytos", "slug": "cytera-cellworks", "former_names": [ "HackScience", "Cytera CellWorks" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/47b55852a1fff0b5b096b7decf0a07ed6cdb0636.png", "website": "https://www.mytos.bio", "all_locations": "London, England, United Kingdom", "long_description": "Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks.\r\n\r\nLast year, patients were cured of Parkinson’s, vision loss, and Type 1 diabetes using stem-cell derived cells. We need 1000x the global capacity to produce these cells, and treat millions of patients. But today these Regenerative Medicines are produced by hand, meaning they’re too expensive and don’t scale.\r\n\r\nMytos has fully automated production of these cells, making it scalable. We have our first manufacturing deal - neurons for treating Parkinson’s - and we’re in conversations with majority of the other top players.", "one_liner": "Robotic human cell manufacturing", "team_size": 26, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1525313281, "tags": [ "Hardware", "IoT", "Biotech", "Automation", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/cytera-cellworks", "api": "https://yc-oss.github.io/api/batches/summer-2018/cytera-cellworks.json" }, { "id": 2015, "name": "Synkrino Biotherapeutics", "slug": "synkrino-biotherapeutics", "former_names": [ "SF17 Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/075baf0892710c7766a502a96091aa7dc37059b8.png", "website": "http://www.synkrino.bio", "all_locations": "Oakland, CA, USA", "long_description": "", "one_liner": "Synkrino's AI, SATIS is a powerful, unbiased discovery system for…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1526443476, "tags": [ "AI-powered Drug Discovery", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/synkrino-biotherapeutics", "api": "https://yc-oss.github.io/api/batches/summer-2018/synkrino-biotherapeutics.json" }, { "id": 2021, "name": "Perception Biosystems", "slug": "perception-biosystems", "former_names": [ "Reformer Therapeutics", "Perception Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6725a216e652408a9448418d0067920052e512a2.png", "website": "https://www.perception.bio", "all_locations": "Palo Alto, CA, USA", "long_description": "Perception Biosystems is democratizing gene therapy through lab automation. Our mission is to accelerate the clinical translation of gene therapy by reinventing its manufacturing and development processes.\r\n\r\nWe're building a robotic lab in the SF Bay Area to translate the large facilities, labor, and regulatory requirements of current gene therapy factories into automated flexible manufacturing systems and code. This enables us to produce gene therapies for use in human clinical trials an order of magnitude faster and cheaper than the current solution – opening up thousands of rare disease targets otherwise thought too rare to pursue.", "one_liner": "Democratizing gene therapy by reinventing its manufacturing and…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527048485, "tags": [ "Gene Therapy", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/perception-biosystems", "api": "https://yc-oss.github.io/api/batches/summer-2018/perception-biosystems.json" }, { "id": 2027, "name": "Dorian Therapeutics", "slug": "dorian-therapeutics", "former_names": [ "Dorian therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2ba869954327a53b835f8f98ae03cf923b67fa1.png", "website": "http://www.doriantherapeutics.com", "all_locations": "San Carlos, CA, USA", "long_description": "", "one_liner": "New therapeutics to rejuvenate tissue and treat age-related diseases ", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527534657, "tags": [ "Anti-Aging", "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Acquired", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/dorian-therapeutics", "api": "https://yc-oss.github.io/api/batches/summer-2018/dorian-therapeutics.json" }, { "id": 2029, "name": "Circumvent", "slug": "circumvent", "former_names": [ "Circumvent Pharmaceuticals" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b5fd725fe8e2cac76ed87eacf3161d3f37da8f61.png", "website": "https://www.circumventpharmaceuticals.com/", "all_locations": "", "long_description": "", "one_liner": "Utilizing monogenic disorders to inform and solve highly complex…", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527534673, "tags": [ "Neurotechnology", "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Unspecified" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/circumvent", "api": "https://yc-oss.github.io/api/batches/summer-2018/circumvent.json" }, { "id": 2031, "name": "Gerostate Alpha", "slug": "gerostate-alpha", "former_names": [ "Gerostate𝝰" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.gerostatealpha.com", "all_locations": "Novato, CA, USA", "long_description": "", "one_liner": "Developing novel therapeutics for aging and chronic disease", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527980791, "tags": [ "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/gerostate-alpha", "api": "https://yc-oss.github.io/api/batches/summer-2018/gerostate-alpha.json" }, { "id": 12036, "name": "Probably Genetic", "slug": "probably-genetic", "former_names": [ "Aiwa Health" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9558e9a7114240a3f1e2a6378bd906ffe21826f3.png", "website": "https://www.probablygenetic.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.", "one_liner": "Patient Intelligence Platform for Genetic Disease ", "team_size": 17, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1541561609, "tags": [ "Health Tech", "Biotech", "Genomics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/probably-genetic", "api": "https://yc-oss.github.io/api/batches/winter-2019/probably-genetic.json" }, { "id": 12046, "name": "Excepgen", "slug": "excepgen", "former_names": [ "Excepgen INC" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/307d19bc5c381fd52d2955c58bdf163b34fac3b7.png", "website": "http://www.excepgen.com", "all_locations": "San Francisco, CA, USA", "long_description": "", "one_liner": "", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1541567035, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/excepgen", "api": "https://yc-oss.github.io/api/batches/winter-2019/excepgen.json" }, { "id": 12355, "name": "YourChoice Therapeutics", "slug": "yourchoice-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5ee153812f550aed3a1d617decff16839415814f.png", "website": "http://ychoicetx.com", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "YourChoice Therapeutics is revolutionizing the global contraceptive market. Our vision is to develop non-hormonal contraceptives to provide both women and men with birth control options that lack the associated risks of hormone-based options but are equally effective. Traditionally, it has been the women’s financial and health burden to have a contraceptive in place. Our first goal is therefore to bring a novel non-hormonal, on-demand and low cost female contraceptive to the market that will substantially improve their quality of life and well-being. Our second goal is to develop the first ever non-surgical and highly effective non-hormonal contraceptive for men. Currently, male contraception is limited to two main options – vasectomy or condoms. Having such options available to both women and men will globally allow for much better family planning, reduce the number of unwanted pregnancies including abortions and therefore reduce costs and ensure contraceptive health and well-being.", "one_liner": "YourChoice therapeutics is revolutionizing the contraceptive market…", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1545442492, "tags": [ "Health Tech", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/yourchoice-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2019/yourchoice-therapeutics.json" }, { "id": 12614, "name": "GEn1E Lifesciences", "slug": "gen1e-lifesciences", "former_names": [ "Gen1E Lifesciences", "Inc.", "Gen1E Lifesciences" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "https://www.gen1e.com", "all_locations": "Palo Alto, CA, USA", "long_description": "GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). \r\n \r\nGEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.\r\n \r\nWith ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.\r\n \r\nThe team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.", "one_liner": "AI platform accelerating therapies for rare & inflammatory diseases.", "team_size": null, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1651188804, "tags": [ "Artificial Intelligence", "Biotech", "Healthcare", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/gen1e-lifesciences", "api": "https://yc-oss.github.io/api/batches/summer-2019/gen1e-lifesciences.json" }, { "id": 12663, "name": "Arpeggio Bio", "slug": "arpeggio-bio", "former_names": [ "Arpeggio Biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/254b79d146cf6fc4b70498fed074d6743d577e13.png", "website": "http://www.arpeggiobio.com", "all_locations": "Boulder, CO, USA", "long_description": "Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted \"undruggable\" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success. ", "one_liner": "Arpeggio Bio develops drugs targeting transcription factors using AI…", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1556764311, "tags": [ "Biotech", "Genomics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/arpeggio-bio", "api": "https://yc-oss.github.io/api/batches/summer-2019/arpeggio-bio.json" }, { "id": 12861, "name": "Asher Bio", "slug": "asher-bio", "former_names": [ "Asher Biotherapeutics", "Asher Biotherapeutics", "Asher Bio", "Asher Biotherapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6ebff96239c6b3bdc84c6e935bf7862294c380cd.png", "website": "https://www.asherbio.com/", "all_locations": "San Francisco, CA, USA; San Carlos, CA, USA", "long_description": "Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. \r\n\r\nAsher Bio is backed by Third Rock Ventures and is located in South San Francisco.", "one_liner": "We build better immunotherapies", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1559270475, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": true, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/asher-bio", "api": "https://yc-oss.github.io/api/batches/summer-2019/asher-bio.json" }, { "id": 13079, "name": "Volumetric", "slug": "volumetric", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "https://volumetricbio.com/", "all_locations": "Houston, TX, USA", "long_description": "About Us\r\nVolumetric is a recognized world leader in building living multicellular tissues, with a focus on replicating discrete functions of the human body for basic mechanistic biology, laboratory testing and screening, and drug development. Founded in 2018 by Bagrat Grigoryan and Jordan Miller as a spin-out from Rice University, the full potential of our work is to build whole human organ replacements for patients, made from their own cells.\r\n\r\nOur Technology and Approach\r\nWe have invented a suite of breakthrough 3D bioprinting technologies, featured on the cover of Science, that can build human tissue with complex blood vessel networks. We are leveraging this technology in the short term to build patient-specific tissues for drug safety and efficacy testing. Patient cells are taken from a biopsy, added to our proprietary 3D printed tissues, and then drug compounds are injected through the blood vessel network to mimic actual drug delivery in humans. Our vision is that our technology will provide rigorous, reproducible, and predictive outcomes for patients, resulting in drastically improved outcomes for diseases like cancer. More broadly, we see the full potential of our mission as being able to produce functional tissue and organ replacements for diseased or damaged vital organs in the body such as the lung, liver, pancreas, kidney, and heart.\r\n", "one_liner": "Volumetric builds living multicellular tissues with a focus on the…", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1591892718, "tags": [ "Biotech", "Healthcare" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Acquired", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/volumetric", "api": "https://yc-oss.github.io/api/batches/winter-2020/volumetric.json" }, { "id": 13178, "name": "Felix Biotechnology", "slug": "felix-biotechnology", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9f10efa48167c6eab9fc52d96d9bf7125ee15db7.png", "website": "https://www.felixbt.com/", "all_locations": "San Francisco, CA, USA", "long_description": "We are building the first end-to-end digital viral design platform to protect the world against the coming threat of antimicrobial resistance.", "one_liner": "We’re creating programmable therapies", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1584145927, "tags": [ "Biotech", "Genomics", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Inactive", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/felix-biotechnology", "api": "https://yc-oss.github.io/api/batches/winter-2020/felix-biotechnology.json" }, { "id": 13216, "name": "General Proximity", "slug": "general-proximity", "former_names": [ "Weatherwax Bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b5e039898073137983f2b9b975353c2be69220f5.png", "website": "https://www.generalproximity.bio/", "all_locations": "San Francisco, CA, USA", "long_description": "", "one_liner": "The next generation of induced-proximity medicines.", "team_size": 15, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1734564466, "tags": [ "Biotech", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/general-proximity", "api": "https://yc-oss.github.io/api/batches/winter-2020/general-proximity.json" }, { "id": 13217, "name": "Altay Therapeutics", "slug": "altay-therapeutics", "former_names": [ "Altay Therapeutics Inc" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.altaytherapeutics.com", "all_locations": "San Francisco, CA, USA; South San Francisco, CA, USA", "long_description": "Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. \r\n\r\nWith a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. \r\n\r\nWe know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. \r\n\r\nWith our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022. \r\n", "one_liner": "Altay develops disease-modifying therapies targeting transcription…", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1583513059, "tags": [ "AI-powered Drug Discovery", "Biotech", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/altay-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2020/altay-therapeutics.json" }, { "id": 13346, "name": "UrbanKisaan", "slug": "urbankisaan", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/46e8aa32e04a21d9a5ef18ccaae02b6b9ddea65d.png", "website": "https://www.urbankisaan.com", "all_locations": "Hyderabad, Telangana, India", "long_description": "UrbanKisaan is an AI-for-plant-biology company. We build foundation models and the physical infrastructure that trains them.\r\n\r\nShipping a single new seed variety takes about ten+ years. Two on germplasm, three on crosses and selection, three or four on field trials, one on regulatory. Inside that decade, prediction and experiment never properly meet. DNA is abundant, phenotype data is scarce and unpaired, and the cycle never trains itself.\r\n\r\nWe closed that loop.\r\n\r\nThree foundation models cover the upstream science. \r\n\r\nAadi is a 48-layer transformer trained from scratch on the public and proprietary corpus of plant genomes; it reads plant DNA and ranks variants before any wet-lab spend. \r\n\r\nJeeva is the genotype-to-phenotype model that turns a seed and a target environment into yield, flowering, maturity, and height with confidence intervals plus per-locus attribution. \r\n\r\nAkash is the geospatial backbone - it maps every pixel of every field to crop class and growing condition.\r\n\r\nTwo pieces of physical infrastructure close the downstream half. \r\n\r\nGeneRush is a controlled-environment chamber engineered for speed: extended photoperiod, optimized temperature, integrated phenomics. Wheat reaches anthesis in 38 days. Breeding programs run 4–6 generations a year instead of 1–2. \r\n\r\nGrowRush takes that same chamber to commercial production scale, where every harvest is also a labelled phenotype training pair flowing back to Jeeva. The unit is paid for by what it grows; the science works because the unit is identical to the chamber the AI was trained on.\r\n\r\nEvery cycle produces proprietary genotype-to-phenotype data the next generation of models needs. The ten-year breeding cycle compresses toward three. We are already commercial", "one_liner": "Foundation models and autonomous chambers for plant biology", "team_size": 53, "industry": "Industrials", "subindustry": "Industrials -> Agriculture", "launched_at": 1583951636, "tags": [ "Biotech", "Agriculture", "AI", "Sustainable Agriculture", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Industrials", "Agriculture" ], "regions": [ "India", "South Asia" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/urbankisaan", "api": "https://yc-oss.github.io/api/batches/winter-2020/urbankisaan.json" }, { "id": 13442, "name": "Isabl", "slug": "isabl", "former_names": [ "Isabl Technologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2ee5c89ed172cfb330b2cb9f0f5e0f1a93886387.png", "website": "http://isabl.io", "all_locations": "New York, NY, USA; Remote", "long_description": "Isabl has developed software that can analyze the entire genome of cancer patients.\r\n\r\nToday, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations.\r\n\r\nOur breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.", "one_liner": "Cancer tests based on whole genome and transcriptome data.", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1652922754, "tags": [ "Biotech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/isabl", "api": "https://yc-oss.github.io/api/batches/winter-2020/isabl.json" }, { "id": 13532, "name": "Living Carbon", "slug": "living-carbon", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/15bec4a7b933065121458477f9bf67ed7382b11f.png", "website": "https://www.livingcarbon.com", "all_locations": "San Francisco, CA, USA", "long_description": "transforming degraded land into high quality environmental assets using end to end operational expertise and precision breeding.", "one_liner": "maximizing biomass on low quality land", "team_size": 40, "industry": "Industrials", "subindustry": "Industrials -> Climate", "launched_at": 1628292917, "tags": [ "Synthetic Biology", "Biotech", "Climate", "Agriculture" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Industrials", "Climate" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/living-carbon", "api": "https://yc-oss.github.io/api/batches/winter-2020/living-carbon.json" }, { "id": 13601, "name": "Equator Therapeutics", "slug": "equator-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2c3115ee7654ff0be36a7d764f8dd7f98b178d2e.png", "website": "https://equatortherapeutics.com/", "all_locations": "San Francisco, CA, USA", "long_description": "We are developing a drug to increase metabolism and burn calories without exercise.\r\n\r\nObesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure.\r\n\r\nOur drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects.\r\n\r\nFor decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.", "one_liner": "We are developing a drug to burn calories and increase metabolism…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1584215124, "tags": [ "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/equator-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2020/equator-therapeutics.json" }, { "id": 13671, "name": "Ansa Biotechnologies", "slug": "ansa-biotechnologies", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2b2832322fabbb9e5f2c1715ec5ca0ffdcf53f34.png", "website": "http://ansabio.com", "all_locations": "Emeryville, CA, USA", "long_description": "Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.", "one_liner": "Next-generation DNA synthesis using enzymes", "team_size": 72, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1660955212, "tags": [ "Synthetic Biology", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/ansa-biotechnologies", "api": "https://yc-oss.github.io/api/batches/winter-2020/ansa-biotechnologies.json" }, { "id": 13672, "name": "Ochre Bio", "slug": "ochre-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d80993cda53fffe2cfd91762d630c27dc21561bf.png", "website": "https://www.ochre-bio.com/", "all_locations": "Oxford, England, United Kingdom", "long_description": "Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.", "one_liner": "RNA medicines for liver diseases", "team_size": 50, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1583988274, "tags": [ "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/ochre-bio", "api": "https://yc-oss.github.io/api/batches/winter-2020/ochre-bio.json" }, { "id": 21881, "name": "Kernal Biologics", "slug": "kernal-biologics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/1534fd5c3c1e4705596c793a4a59a28da388bacf.png", "website": "https://www.kernalbio.com/", "all_locations": "Boston, MA, USA", "long_description": "Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week.\r\n \r\nKernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA.\r\n\r\nWith roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS). ", "one_liner": "Kernal is creating mRNA 2.0 therapies that work in specific cells", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1599762607, "tags": [ "Artificial Intelligence", "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/kernal-biologics", "api": "https://yc-oss.github.io/api/batches/summer-2020/kernal-biologics.json" }, { "id": 22045, "name": "Nephrogen", "slug": "nephrogen", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ce4f8b04c9fefa06f0088d04f45b91af1e3fe8aa.png", "website": "http://www.nephrogenbiotech.com", "all_locations": "New York, NY, USA", "long_description": "Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. \r\n\r\nNephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.", "one_liner": "Curative genetic medicines for kidney diseases", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1660881251, "tags": [ "Gene Therapy", "CRISPR", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/nephrogen", "api": "https://yc-oss.github.io/api/batches/summer-2020/nephrogen.json" }, { "id": 22111, "name": "Pardes Biosciences", "slug": "pardes-bio", "former_names": [ "Pardes Biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/7a90b132bd3ef57761690e68c3355e7471e2abf7.png", "website": "http://www.pardesbio.com", "all_locations": "San Francisco, CA, USA; Remote", "long_description": "We make oral drugs to treat and prevent viral infections - like COVID-19. ", "one_liner": "We break viruses", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1630014282, "tags": [ "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": true, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Public", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/pardes-bio", "api": "https://yc-oss.github.io/api/batches/summer-2020/pardes-bio.json" }, { "id": 22305, "name": "Future Fields", "slug": "future-fields", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/27598374d1722327901a24bfb15f9fd42bed8beb.png", "website": "https://www.futurefields.io/about", "all_locations": "Edmonton, AB, Canada", "long_description": "Future Fields has developed the world's first multicellular advanced biomanufacturing platform for the production of the most challenging recombinant proteins. We help companies in biotech, life sciences, and pharma by manufacturing their proteins. ", "one_liner": "We make unmakeable proteins with radical advanced biomanufacturing. ", "team_size": 34, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1596382991, "tags": [ "Biotech", "Manufacturing", "Climate" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "Canada", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/future-fields", "api": "https://yc-oss.github.io/api/batches/summer-2020/future-fields.json" }, { "id": 22617, "name": "Serna Bio", "slug": "serna-bio", "former_names": [ "Ladder Therapeutics (LTX)" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e5c345ecf4dc0bf6d96b3cb2f1e7485d78c1449d.png", "website": "http://serna.bio", "all_locations": "Ontario, CA, USA; Remote", "long_description": "Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities. \r\n", "one_liner": "Genetic Medicine with Small Molecules ", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1659537090, "tags": [ "Biotech", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/serna-bio", "api": "https://yc-oss.github.io/api/batches/winter-2021/serna-bio.json" }, { "id": 22618, "name": "Trestle Biotherapeutics", "slug": "trestle-biotherapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c0912ac989e9c9882feee4241222a8356814f6cb.png", "website": "http://www.trestlebio.com", "all_locations": "San Diego, CA, USA", "long_description": "We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.", "one_liner": "Bioengineered kidneys for patients with kidney failure", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1615929032, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/trestle-biotherapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2021/trestle-biotherapeutics.json" }, { "id": 22764, "name": "Valink Therapeutics", "slug": "valink-therapeutics", "former_names": [ "SpyCombinator", "LiliumX" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4fdbac90b07fa4233736c11be944db20adb49e3b.png", "website": "https://www.valinktx.com/", "all_locations": "Boston, MA, USA", "long_description": "Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.", "one_liner": "Discovering bispecific antibody drug-conjugates (BsADC) against cancer", "team_size": 15, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1614618602, "tags": [ "Biotech", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/valink-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2021/valink-therapeutics.json" }, { "id": 23263, "name": "Entelexo Biotherapeutics", "slug": "entelexo-biotherapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2ef38251e4060b4827ae3ce45f0e73e1f6f1cb2d.png", "website": "https://www.entelexo.com/", "all_locations": "Irvine, CA, USA", "long_description": "Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.", "one_liner": "Creating a New Class of Drugs to Address Incurable Autoimmune Diseases", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1614964227, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/entelexo-biotherapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2021/entelexo-biotherapeutics.json" }, { "id": 23611, "name": "Reshape Biotech", "slug": "reshape-biotech", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e65681d8e11f4598b0cec0afd8633f5b9d77590c.png", "website": "http://reshapebiotech.com/", "all_locations": "Copenhagen, Denmark", "long_description": "Reshape Biotech builds lab robots that automate the everyday tasks of microbiologists, from filling plates to analyzing images.\r\nOther companies try to sell “one lab robot that does everything”. But those robots become so complicated that they sit unused on the shelf. We build one robot for each function, which makes them easy to use.\r\n", "one_liner": "Robots that automate the everyday tasks of microbiologists.", "team_size": 40, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1614678485, "tags": [ "Robotics", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "Denmark", "Europe", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/reshape-biotech", "api": "https://yc-oss.github.io/api/batches/winter-2021/reshape-biotech.json" }, { "id": 23945, "name": "Talus Bio", "slug": "talus-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6677b768e2a0c2a30de4f32fc3f4f2dce1baea6a.png", "website": "https://www.talus.bio", "all_locations": "Seattle, WA, USA", "long_description": "We have built a platform that enables drug discovery and development for previously undruggable genome regulators (\"the regulome\"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment. ", "one_liner": "Discovering drugs that target the DNA regulome", "team_size": 16, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1629819925, "tags": [ "Biotech", "Genomics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/talus-bio", "api": "https://yc-oss.github.io/api/batches/summer-2021/talus-bio.json" }, { "id": 23951, "name": "Mindstate Design Labs", "slug": "mindstate-design-labs", "former_names": [ "Kykeon Biotechnologies Inc.", "Kykeon Biotechnologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f3509dac4b76d442f8f0aa79c2bda0b827e78798.png", "website": "http://mindstate.design", "all_locations": "San Francisco, CA, USA", "long_description": "We're making every therapeutically valuable emotion available on demand in pharmaceutical form.\r\n\r\nOur Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states.\r\n\r\nOur lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination \"emotions in a bottle\" such as empathy, awe, clarity, or beauty.", "one_liner": "Clinical-stage AI neuroengineering platform", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1629815779, "tags": [ "Machine Learning", "Mental Health Tech", "Biotech", "Therapeutics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/mindstate-design-labs", "api": "https://yc-oss.github.io/api/batches/summer-2021/mindstate-design-labs.json" }, { "id": 24008, "name": "Catena Biosciences", "slug": "catena-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f1d289877a701c3b0826470c1e3ff501de0e4759.png", "website": "https://www.catenabiosciences.com/", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.\r\n", "one_liner": "Using protein coupling to build new therapies", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1624576033, "tags": [ "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/catena-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2021/catena-biosciences.json" }, { "id": 24081, "name": "Parallel Bio", "slug": "parallel-bio", "former_names": [ "Parallel Biosystems Inc" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/983561db384b2274b11c61cd0cad3af0a429c991.png", "website": "http://parallel.bio", "all_locations": "San Francisco, CA, USA", "long_description": "Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development. \r\n\r\nParallel Bio’s platform overcomes the core limitations of traditional animal testing, which fails to encapsulate the complexity of human biology. The company is building internal pipelines of novel disease targets and drug candidates in both cancer and autoimmune disease, while collaborating with pharmaceutical companies to evaluate therapies directly in human systems to reduce the cost and risk of clinical trials. \r\n\r\nBased in San Francisco, the company was founded in 2021 by two of the world’s leading experts in replacing animal models with human-first platforms.", "one_liner": "Using the immune system to cure disease", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1626811179, "tags": [ "AI-powered Drug Discovery", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/parallel-bio", "api": "https://yc-oss.github.io/api/batches/summer-2021/parallel-bio.json" }, { "id": 24082, "name": "BLUUMBIO", "slug": "bluumbio", "former_names": [ "BluumBio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6ab459fbbd7388fc0c0bce2a0543bcf07bd6fdc4.png", "website": "http://www.bluumbio.com", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "Our mission\r\n\r\n-To ensure current and future generations have access to clean soil, water & air.\r\n\r\n-To protect and restore earth's beautiful and diverse ecosystems.\r\n\r\n-To undo the harm of industrial activity on the planet and ensure future industrial activities are more sustainable.\r\n\r\nOur research\r\n\r\n-We develop new bio-based solutions that break down and remove toxic chemicals from the environment.  We also develop bioreactor based solutions which remove toxins from industrial production pipelines, ensuring contaminants are never released into the environment.\r\n\r\n-To do this, we've partnered with Nature. Specifically, we have harnessed the power of one of Nature's smallest but most powerful technologies: enzymes. Enzymes are everywhere. They break down the food in your stomach, remove dirt from your clothes, and make our beer. At BluumBio, we look for enzymes found in bacteria, algae, plants and other living organisms that naturally degrade toxic chemicals. We then make these enzymes work better in the lab and come up with develop new applications for these technologies.", "one_liner": "We make bacteria and plants that clean up pollution.", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1626190862, "tags": [ "Biotech", "Sustainability" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/bluumbio", "api": "https://yc-oss.github.io/api/batches/summer-2021/bluumbio.json" }, { "id": 24138, "name": "Epinoma", "slug": "epinoma", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/294fcfc406e637a4349c10bf905e02f36d177455.png", "website": "https://www.epinoma.com/", "all_locations": "San Francisco, CA, USA", "long_description": "", "one_liner": "We engineer proteins that control the operating system of biology. ", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1629821855, "tags": [ "Synthetic Biology", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/epinoma", "api": "https://yc-oss.github.io/api/batches/summer-2021/epinoma.json" }, { "id": 24185, "name": "Micro Meat", "slug": "micro-meat", "former_names": [ "Micro Meat Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ab9214122c1f44be841827f0b43c68e15d29f063.png", "website": "http://www.micromeat.com", "all_locations": "Monterrey, N.L., Mexico", "long_description": "", "one_liner": "Technologies for scaling up cultured/clean meat production", "team_size": 0, "industry": "Industrials", "subindustry": "Industrials -> Agriculture", "launched_at": 1625672983, "tags": [ "Hard Tech", "Cultured Meat", "Biotech", "Climate", "Food Tech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Inactive", "industries": [ "Industrials", "Agriculture" ], "regions": [ "Mexico", "Latin America", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/micro-meat", "api": "https://yc-oss.github.io/api/batches/summer-2021/micro-meat.json" }, { "id": 24188, "name": "Pirouette Pharma", "slug": "pirouette-pharma", "former_names": [ "Pirouette Medical, LLC.", "Pirouette Medical" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6d5c45afdf23c42aacf00d8b2a17adc32893a852.png", "website": "https://www.pirouettepharma.com/", "all_locations": "Boston, MA, USA", "long_description": "At Pirouette, we have developed a low-profile, disk-shaped, rugged injection device with a patient-centric focus on affordability, portability, and usability. The patented device, based on extensive patient input, is designed to make administering an injection as easy as pushing a button. This allows individuals with limited or no training to easily and intuitively perform an injection on themselves or others.", "one_liner": "We make injections as easy as pushing a button!", "team_size": 9, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1624370517, "tags": [ "Health Tech", "Medical Devices", "Biotech", "Healthcare" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/pirouette-pharma", "api": "https://yc-oss.github.io/api/batches/summer-2021/pirouette-pharma.json" }, { "id": 24368, "name": "Yemaachi Biotechnology", "slug": "yemaachi-biotechnology", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0f20c99ceb3dc4f5663a9b43329248c249511272.png", "website": "https://yemaachi.com/", "all_locations": "Accra, Greater Accra Region, Ghana", "long_description": "Yemaachi Biotech is diversifying and expanding access to precision cancer diagnostics and therapeutics by collecting and sequencing samples from all across Africa, which is the most genetically diverse population on the planet. We then use this data to either optimize existing diagnostic tests, or help other companies discover new ones.\r\nWith our research activities based in Africa, we are able to leverage access to the most genetically diverse population on the planet to build a first-of-its-kind clinical and molecular knowledgebase on cancer among African people.", "one_liner": "Diversifying precision cancer diagnostics and treatments", "team_size": 16, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1627837386, "tags": [ "Biotech", "Diagnostics", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Ghana", "Africa" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/yemaachi-biotechnology", "api": "https://yc-oss.github.io/api/batches/summer-2021/yemaachi-biotechnology.json" }, { "id": 24467, "name": "Harmonic Discovery", "slug": "harmonic-discovery", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/dbebdea5cbd5fee23eff97b4d514d27fb9652ed0.png", "website": "http://harmonicdiscovery.com", "all_locations": "New York, NY, USA; Remote", "long_description": "We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. \r\n\r\nWe are building a computational-experimental platform to design therapeutics that can target several disease-causing proteins at once. By designing multi-specific drugs, we are able to create therapeutics that are more efficacious and safer than existing medicines. \r\n", "one_liner": "Multi-targeted therapeutics to treat complex diseases", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1648254586, "tags": [ "AI-powered Drug Discovery", "Biotech", "Healthcare", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/harmonic-discovery", "api": "https://yc-oss.github.io/api/batches/summer-2021/harmonic-discovery.json" }, { "id": 24628, "name": "Kiwi Biosciences", "slug": "kiwi-biosciences", "former_names": [ "Kiwi Bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/dbab0dcef0041ce58d73ba3b8e05f5279e22f0bf.png", "website": "https://www.fodzyme.com", "all_locations": "Boston, MA, USA", "long_description": "Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food. ", "one_liner": "Patent-pending enzymes to break down common dietary triggers", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Consumer Health and Wellness", "launched_at": 1628891422, "tags": [ "Biotech", "Food Tech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Consumer Health and Wellness" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/kiwi-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2021/kiwi-biosciences.json" }, { "id": 24705, "name": "Sensible Biotechnologies", "slug": "sensible-biotechnologies", "former_names": [ "Genbiotics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/45d14c57e3b4e2739c65c0bb84a511608548ffa2.png", "website": "https://sensible.bio", "all_locations": "Oxford, England, United Kingdom", "long_description": "The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.", "one_liner": "Unlocking the next generation of mRNA medicines", "team_size": 24, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1680519323, "tags": [ "Synthetic Biology", "Biotech", "Manufacturing", "Therapeutics", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/sensible-biotechnologies", "api": "https://yc-oss.github.io/api/batches/summer-2021/sensible-biotechnologies.json" }, { "id": 24727, "name": "Output Biosciences", "slug": "output", "former_names": [ "Jingu Health" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/990074a168ed566a1898edae4ddc84a3de0b15c3.png", "website": "https://www.outputbio.com/", "all_locations": "New York, NY, USA", "long_description": "Output Biosciences is pioneering Biologically-Aware Generative AI to finally understand complex biological systems. Our new generative AI architecture can handle the extremely long, nonlinear, fragmented, and high dimensional data of biological systems. We are building Large Biological Models that can generate breakthrough medicines and transform the way we diagnose, treat and prevent disease. ", "one_liner": "Teaching Generative AI the Language of Biology", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1628006072, "tags": [ "AI-powered Drug Discovery", "Generative AI", "Biotech", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/output", "api": "https://yc-oss.github.io/api/batches/summer-2021/output.json" }, { "id": 24795, "name": "SFA Therapeutics", "slug": "sfa-therapeutics-inc", "former_names": [ "SFA Therapeutics, Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5873834b208e59808a81e6f7b65403be4dd9fc78.png", "website": "https://sfatherapeutics.com/", "all_locations": "Philadelphia, PA, USA", "long_description": "SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.", "one_liner": "Regulating the immune system to block cancer & autoimmune diseases", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1624038758, "tags": [ "AI-powered Drug Discovery", "Anti-Aging", "Biotech", "Health & Wellness", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": true, "app_answers": true, "question_answers": true, "url": "https://www.ycombinator.com/companies/sfa-therapeutics-inc", "api": "https://yc-oss.github.io/api/batches/summer-2021/sfa-therapeutics-inc.json" }, { "id": 24820, "name": "Medium Biosciences", "slug": "medium-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0f30f00dbe44cde67296a43e445c0bb0dc14f9b5.png", "website": "http://medium.bio", "all_locations": "San Francisco, CA, USA", "long_description": "We turn advances in AI and protein design into experimentally validated molecular tools, partnering with research teams and diagnostic developers to deliver high-performance affinity reagents in weeks, not months.\r\n", "one_liner": "AI-designed Affinity Reagents", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1630004252, "tags": [ "Artificial Intelligence", "Machine Learning", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/medium-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2021/medium-biosciences.json" }, { "id": 25321, "name": "Rosebud Biosciences", "slug": "rosebud-biosciences", "former_names": [ "Rosebud Biosciences Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4227cb01a0152cba77ed3792cf3513cba3e07e77.png", "website": "https://rosebudbiosciences.com/", "all_locations": "San Francisco, CA, USA; San Carlos, CA, USA", "long_description": "Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already led to the discovery of a drug target in a pediatric heart disease that could not have been found using traditional disease models.", "one_liner": "Growing micro-organs to find new drugs", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1646685843, "tags": [ "AI-powered Drug Discovery", "Pediatrics", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": true, "app_answers": true, "question_answers": false, "url": "https://www.ycombinator.com/companies/rosebud-biosciences", "api": "https://yc-oss.github.io/api/batches/winter-2022/rosebud-biosciences.json" }, { "id": 25331, "name": "Engage Bio", "slug": "engage-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e95b5dd7ee1a5f617dc0a83136e30199f883050a.png", "website": "http://engagebio.com", "all_locations": "San Francisco, CA, USA", "long_description": "Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.\r\n \r\nIn 2026 Engage was acquired by Eli Lilly.", "one_liner": "Potent, durable, and redosable non-viral genetic medicines", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1647555290, "tags": [ "Synthetic Biology", "Biotech", "Healthcare", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Acquired", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/engage-bio", "api": "https://yc-oss.github.io/api/batches/winter-2022/engage-bio.json" }, { "id": 25349, "name": "Brown Foods", "slug": "brown-foods", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/8c7ebf13baa0b5e29608fd2d781b14ba29cc015b.png", "website": "https://unrealmilk.com/", "all_locations": "Boston, MA, USA", "long_description": "Brown Foods is a Stanford, Rice University and IIT Delhi alumni venture creating UnReal Milk - 'real milk' made using mammalian cell culture, AI enabled. They are the world's 1st company to produce cow-free whole milk in lab (Forbes). Targeting the $700 billion dairy market and $22 billion alternate dairy market with UnReal Milk - which could be converted into butter, cheese, ice-creams etc. and has taste and texture exactly like conventional dairy - unlike any of the plant based milks like oat milk or soy milk. Also, no animal cruelty and 82% lower carbon foot-print!\r\n\r\nUsing the same technology, they have also created real human milk targeting the $80 billion infant formula market. And who knows if adults also start drinking human milk in future!", "one_liner": "Making 'REAL' Cow and Human Milk!", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1644325519, "tags": [ "Cellular Agriculture", "Biotech", "Climate", "Food Tech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/brown-foods", "api": "https://yc-oss.github.io/api/batches/winter-2022/brown-foods.json" }, { "id": 25399, "name": "Invert", "slug": "invert", "former_names": [ "Invert Bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/1e1a589d7f48cf8cc7fb3658ec8dea0855d526a0.png", "website": "http://www.invertbio.com/", "all_locations": "San Francisco, CA, USA; Remote", "long_description": "We build software to manage, analyze, and optimize bioprocessing data. Our initial customers are bio-industrial companies, who produce various products in bioreactors.\r\n\r\n", "one_liner": "Data analytics software for biomanufacturing.", "team_size": 25, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1648234072, "tags": [ "Cellular Agriculture", "Machine Learning", "Synthetic Biology", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/invert", "api": "https://yc-oss.github.io/api/batches/winter-2022/invert.json" }, { "id": 25448, "name": "HypaHub", "slug": "hypahub", "former_names": [ "HypaHub, Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5a364403fcd1dfaabe90af51ec8af68eac5364cf.png", "website": "https://www.hypahub.com", "all_locations": "Sunnyvale, CA, USA", "long_description": "HypaHub is a Cloud-Based Bioinformatics and AI Platform. It is the first HIPAA-compliant Bioinformatics SaaS that runs natively on users' clouds, providing both operation- and price-transparency. \r\n\r\nOur product is a one-stop shop to access complex technologies designed for scientists building data applications or performing data analytics to extract insights. It automates the creation and manages the operation of computing resources, eliminating the need for enterprises to set up and maintain a high-end R&D cloud infrastructure.", "one_liner": "A Cloud-Based Bioinformatics and AI Platform ", "team_size": 6, "industry": "B2B", "subindustry": "B2B -> Analytics", "launched_at": 1654727846, "tags": [ "Machine Learning", "Biotech", "Analytics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Acquired", "industries": [ "B2B", "Analytics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/hypahub", "api": "https://yc-oss.github.io/api/batches/winter-2022/hypahub.json" }, { "id": 25449, "name": "Alixia", "slug": "alixia", "former_names": [ "Guided Clarity" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ff4093c59629c7638e73b36eb069911e0922c140.png", "website": "http://www.alixia.com", "all_locations": "San Francisco, CA, USA", "long_description": "Our compounds disrupt the metabolic and\r\ninflammatory triggers in both cancer and quasi-cancerous\r\ncells in the tumor microenvironment. By impacting multiple cell\r\ntypes, we are enabling effective, lasting cancer treatments.", "one_liner": "Targeting the Tumor Ecosystem to address cancer drug resistance.", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1648247483, "tags": [ "Biotech", "Therapeutics", "Drug discovery", "Oncology", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/alixia", "api": "https://yc-oss.github.io/api/batches/winter-2022/alixia.json" }, { "id": 25700, "name": "Alga Biosciences", "slug": "alga-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d29ef143dd8568dbe7b1530b64fd7ea5989d69b3.png", "website": "https://www.alga.bio/", "all_locations": "Berkeley, CA, USA; San Francisco, CA, USA", "long_description": "Alga Biosciences is a fast-moving startup focused on transforming the agricultural industry. Our mission is to make an immediate, dramatic impact on global methane emissions produced by enteric fermentation in partnership with the cattle industry. We believe in leveraging biology to tackle the world’s biggest problems.", "one_liner": "We stop cows from burping methane.", "team_size": 6, "industry": "Industrials", "subindustry": "Industrials -> Climate", "launched_at": 1645592930, "tags": [ "Biotech", "Climate", "Agriculture" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Industrials", "Climate" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/alga-biosciences", "api": "https://yc-oss.github.io/api/batches/winter-2022/alga-biosciences.json" }, { "id": 25864, "name": "Torpedo Therapeutics", "slug": "torpedo-therapeutics", "former_names": [ "Neural Dynamics Technologies LLC", "Neural Dynamics", "Neural Dynamics Technologies", "Neural Dynamics Technologies Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/29b16aa346e71b9adabcb4e4ad8246dc1ea325db.png", "website": "https://www.torpedotherapeutics.com", "all_locations": "Boston, MA, USA", "long_description": "We are building high-precision implantable neuromodulation devices that can sense and stimulate neural activity in the brain with the goal of transforming the efficacy and adoption of deep brain stimulation (DBS), an existing FDA-approved therapy used to treat Parkinson’s, essential tremor and epilepsy. \r\n\r\n\r\n", "one_liner": "High-precision, closed-loop neuromodulation devices", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Medical Devices", "launched_at": 1645109962, "tags": [ "Neurotechnology", "Medical Devices", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Medical Devices" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/torpedo-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2022/torpedo-therapeutics.json" }, { "id": 25865, "name": "Andson Biotech", "slug": "andson-biotech", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/8495f5832705b897265e143f4ea26b9403783542.png", "website": "http://www.andsonbiotech.com", "all_locations": "Atlanta, GA, USA", "long_description": "Andson Biotech helps pharmaceutical companies measure difficult to detect chemicals that they need to measure while developing and manufacturing drugs like cell-therapies or biologics. Drug companies want to use our technologies to get fast and accurate chemical measurements they do thousands of times per day for drug development and quality control. ", "one_liner": "Empowering Mass Spec for Biotech and Beyond", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1644435477, "tags": [ "Gene Therapy", "Hard Tech", "Biotech", "Healthcare", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/andson-biotech", "api": "https://yc-oss.github.io/api/batches/winter-2022/andson-biotech.json" }, { "id": 26122, "name": "Origami Therapeutics, Inc.", "slug": "origami-therapeutics-inc", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ec01151ea9fbf839d64b9d2a17dedc03fb322eeb.png", "website": "http://origamitherapeutics.com", "all_locations": "San Diego, CA, USA", "long_description": "Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.", "one_liner": "Oral drugs to halt neurodegeneration", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1647386798, "tags": [ "Biotech", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/origami-therapeutics-inc", "api": "https://yc-oss.github.io/api/batches/winter-2022/origami-therapeutics-inc.json" }, { "id": 26554, "name": "Cisterna Biologics", "slug": "cisterna-biologics", "former_names": [ "Cisterna Biologics LLC", "Cisterna Biologic" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/fa3a5ab85434b41a7ce57fae09e3c4645bc55f02.png", "website": "http://www.cisternabx.com", "all_locations": "San Diego, CA, USA", "long_description": "Founded in 2022 and based in San Diego, California, Cisterna Biologics is a technology company. It aims to solve some of the challenges currently facing the biotech industry to develop mRNA-based therapeutics – quality, quantity, longevity and cost of mRNA. As mRNA technology matures, it becomes imperative that these issues are solved so we can fully explore mRNA's endless possibilities as a therapeutic.\r\n\r\nCisterna uses proprietary technologies to either remove a contaminant at its source or replace the source itself. For example, to remove double-stranded RNA (dsRNA), we use ribozymes - molecular scissors - to precisely cut the mRNA at its 3’ end. This assures not only 3’ homogeneity, but also eliminates dsRNA, which are primarily produced due to self-templated additions at the 3’ end. Utilizing a PCR-like system to amplify the DNA template in large quantities eliminates the requirement for plasmid enrichment in bacteria, the prime source of endotoxin contamination. These are just a few examples of Cisterna’s powerful technologies being used to achieve our goal of 10x higher quality mRNA for therapeutic application.", "one_liner": "High quality mRNA for therapeutic application", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1656370216, "tags": [ "Synthetic Biology", "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/cisterna-biologics", "api": "https://yc-oss.github.io/api/batches/summer-2022/cisterna-biologics.json" }, { "id": 26675, "name": "Birch Biosciences", "slug": "birch-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6d5ede074951640a2e67e11927c78affb1e31b81.png", "website": "http://www.birchbiosciences.com", "all_locations": "Portland, OR, USA", "long_description": "Birch Biosciences engineers enzymes for plastic recycling using synthetic biology and machine learning. Our enzymes function as high performance “molecular scissors” that efficiently break down plastic polymers into chemical building blocks that can be used to manufacture high quality recycled plastic products. Today, plastic manufacturing is unsustainable and a major driver of climate change. Birch Biosciences is developing an economical end-to-end plastic recycling process that reduces carbon emissions by 70% and enables a circular plastic economy.\r\n", "one_liner": "We recycle plastic using engineered enzymes", "team_size": 10, "industry": "Industrials", "subindustry": "Industrials -> Climate", "launched_at": 1656393851, "tags": [ "Machine Learning", "Synthetic Biology", "Biotech", "Climate", "ClimateTech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Industrials", "Climate" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/birch-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2022/birch-biosciences.json" }, { "id": 26734, "name": "Serinus Biosciences", "slug": "serinus-biosciences", "former_names": [ "Serinus" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b6e7bac94ec8bfc7378ed11602bae7ea50215536.png", "website": "http://www.serinus.bio", "all_locations": "New York, NY, USA", "long_description": "Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.", "one_liner": "Combinations therapy by rational design", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1656454958, "tags": [ "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/serinus-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2022/serinus-biosciences.json" }, { "id": 26751, "name": "Signatur Biosciences", "slug": "signatur-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3bad55d9462a3252670af9b86ed4d9abc2a388f4.png", "website": "https://www.signatur.bio/", "all_locations": "London, England, United Kingdom", "long_description": "We make precision diagnostics more accessible, starting with breast cancer prognosis. Current tests that guide the use of therapy are really slow and expensive because they need to be run in complex centralized facilities. Our tests are designed to be easily run by local hospital labs, reducing turnaround time from over three weeks to a few days and for a fraction of the price.", "one_liner": "Simple tests for complex diseases.", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1657207796, "tags": [ "Biotech", "Healthcare", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/signatur-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2022/signatur-biosciences.json" }, { "id": 26769, "name": "ALT TEX", "slug": "alt-tex", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6cf48f1bdd01fd17e94a2956a2f313bda002e407.png", "website": "https://thealttex.com/", "all_locations": "Toronto, ON, Canada", "long_description": "ALT TEX is a Toronto-based biomaterials startup that has developed the world’s first biodegradable and carbon neutral fabric, engineered from the world’s largest landfill contributor - food waste. Polyester alone makes up 60% of the $2.5 trillion fashion industry and is the biggest blocker preventing brands from meeting sustainability mandates. The patent-pending ALT TEX fermentation technology creates a polyester alternative that works with the existing infrastructure to supply a sustainable, high performance and cost competitive polyester replacement to fashion brands, at scale. \r\n\r\nThe product solves key problems for fashion brands, consumers, and the environment:\r\n\r\n(1) Fashion brands: ALT TEX sells fabric to fashion brands, allowing them to differentiate via sustainable options (sustainable fashion growing 11% CAGR) and hit sustainability targets, without sacrificing performance or changing their current supply chain.\r\n\r\n(2) Consumer: The ALT TEX fabric is projected to be half the price vs. other specialized sustainable alternatives (due to low-cost input and scalability), meaning greater accessibility.\r\n\r\n(3) Environment: A single shirt produced with ALT TEX fabric can divert 1 kg of food waste from landfills, 9 kg of carbon emissions from the air, and 4 g of micro-plastics from our waterways.\r\n\r\nCo-founders Myra and Avneet have worked together managing teams and projects for six years, with backgrounds in serial entrepreneurship, corporate sales at Fortune 500 companies, textile manufacturing and biochemistry. To date, ALT TEX has created their first fabric prototype that’s 70% stronger than cotton, secured $1M in LOIs and raised $2.3M.", "one_liner": "Biodegradable and carbon neutral textiles, engineered from food waste.", "team_size": 10, "industry": "Industrials", "subindustry": "Industrials -> Climate", "launched_at": 1659631637, "tags": [ "Carbon Capture and Removal", "Bioplastic", "Biotech", "Climate", "Food Tech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Industrials", "Climate" ], "regions": [ "Canada", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/alt-tex", "api": "https://yc-oss.github.io/api/batches/summer-2022/alt-tex.json" }, { "id": 26912, "name": "Quinn", "slug": "quinn", "former_names": [ "iollo" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5bd3e4de086fbafd70c63dbae211f55425382f05.png", "website": "https://www.quinnbio.com", "all_locations": "San Francisco, CA, USA", "long_description": "Quinn makes the highest-stakes scientific decisions in drug development. Which drugs to bet on, what to develop next, how to get them to patients. In days instead of months.", "one_liner": "The AI that delivers pharma R&D decisions in days, not months", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1656567327, "tags": [ "Artificial Intelligence", "Generative AI", "Biotech", "Enterprise" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/quinn", "api": "https://yc-oss.github.io/api/batches/summer-2022/quinn.json" }, { "id": 27092, "name": "Lamin", "slug": "lamin", "former_names": [ "Lamin Labs" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/65bf3f581eea5d1a5b7640c508e3fc0e7c8930f9.png", "website": "https://lamin.ai", "all_locations": "", "long_description": "Query, trace, and validate datasets and models at scale. Automate context for agents and humans.\r\n\r\nOne API: lakehouse, lineage, feature store, ontologies, bio-registries & formats.", "one_liner": "Open data lakehouse for biology", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare IT", "launched_at": 1655969538, "tags": [ "Developer Tools", "Machine Learning", "Biotech", "Open Source", "Data Engineering" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Healthcare IT" ], "regions": [ "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/lamin", "api": "https://yc-oss.github.io/api/batches/summer-2022/lamin.json" }, { "id": 27201, "name": "Lavo Life Sciences", "slug": "lavo-life-sciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/590ccfba5d4f0f97ed00fd962f2fdea307dbea2f.png", "website": "https://www.lavo.ai/", "all_locations": "", "long_description": "Lavo Life Sciences runs simulations of drug molecules on computers. Pharma companies use these simulations to guide their experiments and ultimately save time and money in the lab. This will de-risk and expedite clinical trials and FDA approval.", "one_liner": "AI for drug formulation", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1674082073, "tags": [ "AI-powered Drug Discovery", "Machine Learning", "Biotech", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Inactive", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "Unspecified" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/lavo-life-sciences", "api": "https://yc-oss.github.io/api/batches/winter-2023/lavo-life-sciences.json" }, { "id": 27263, "name": "Guardian Bio", "slug": "guardian-bio", "former_names": [ "GuardianBio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/686bc0e4b74ba3953559c1bb8515351010e84b61.png", "website": "http://www.guardian-bio.com", "all_locations": "Boston, MA, USA", "long_description": "Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. \r\n\r\nGuardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. \r\n\r\nOur therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.", "one_liner": "Dendritic cell-based platform for cancer therapy ", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1657134176, "tags": [ "Biotech", "Healthcare", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/guardian-bio", "api": "https://yc-oss.github.io/api/batches/summer-2022/guardian-bio.json" }, { "id": 27671, "name": "Miracle", "slug": "miracle", "former_names": [ "Miracle Health" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/708f104e98cf6195b515828cadc85b8d47cfc8d4.png", "website": "http://www.miracleml.com", "all_locations": "San Francisco, CA, USA", "long_description": "Miracle is the control room for clinical trials. Our platform consolidates data from multiple trial systems into real-time dashboards, delivering automated insights that empower clinical-stage biopharmaceutical companies to streamline operations, reduce manual workflows, and accelerate data-driven decision-making. By transforming complex trial data into actionable insights, Miracle helps biopharma teams speed up clinical trials, and ultimately, improve patient outcomes.", "one_liner": "Accelerate clinical trials with real-time, actionable insights", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1677015940, "tags": [ "SaaS", "B2B", "Biotech", "Healthcare" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/miracle", "api": "https://yc-oss.github.io/api/batches/winter-2023/miracle.json" }, { "id": 28037, "name": "Diffuse Bio", "slug": "diffuse-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/961a0aa4b25ffd0049a0526af8ad2406763125f4.png", "website": "http://diffuse.bio", "all_locations": "San Carlos, CA, USA", "long_description": "Diffuse is building generative AI for protein design. Our mission is to build AI systems that engineer new and useful proteins with unprecedented control and accuracy. Our team has been behind breakthroughs in AI protein design for the past 7 years, including the first experimental validation of AI-generated proteins and diffusion models for protein structure and sequence. ", "one_liner": "Generative AI for protein design", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1673220633, "tags": [ "AI-powered Drug Discovery", "Deep Learning", "Generative AI", "Machine Learning", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/diffuse-bio", "api": "https://yc-oss.github.io/api/batches/winter-2023/diffuse-bio.json" }, { "id": 28158, "name": "Adventris Pharmaceuticals", "slug": "adventris-pharmaceuticals", "former_names": [ "Elimivax" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5c8bb0a987c29df94410bb9cc6ab7db9eb0d6478.png", "website": "https://adventris.com", "all_locations": "Baltimore, MD, USA", "long_description": "Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first \"off-the-shelf\" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths.\r\n\r\nIf you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com", "one_liner": "Adventris makes cancer vaccines", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1675190671, "tags": [ "Biotech", "Healthcare", "Therapeutics", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/adventris-pharmaceuticals", "api": "https://yc-oss.github.io/api/batches/winter-2023/adventris-pharmaceuticals.json" }, { "id": 28159, "name": "Invitris", "slug": "invitris", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b31c6e14e61e0a7e292383c88d7094914a492565.png", "website": "https://invitris.com/", "all_locations": "Munich, BY, Germany", "long_description": "Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.\r\n\r\nOur killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined. ", "one_liner": "Creating new protein-based drugs at scale", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1678475135, "tags": [ "Biotech", "Nanotechnology", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "Germany", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/invitris", "api": "https://yc-oss.github.io/api/batches/winter-2023/invitris.json" }, { "id": 28205, "name": "Modulari-T", "slug": "modulari-t", "former_names": [ "Modulari-T Biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/cdfde836f1d168c7ec0299ab6b4daf90d112f929.png", "website": "https://modularit.bio", "all_locations": "Montreal, QC, Canada; San Francisco, CA, USA", "long_description": "Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise.\r\n\r\nModulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue.\r\n\r\nModulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.", "one_liner": "We teach your immune system to attack and cure cancer", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1675126815, "tags": [ "Gene Therapy", "Cell Therapy", "Synthetic Biology", "Biotech", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Canada", "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/modulari-t", "api": "https://yc-oss.github.io/api/batches/winter-2023/modulari-t.json" }, { "id": 28425, "name": "Pando Bioscience", "slug": "pando-bioscience", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/fcb2bf6569db61c3592824679114d563e4d1438c.png", "website": "https://pando.bio/", "all_locations": "Boston, MA, USA", "long_description": "Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.", "one_liner": "Gen-AI Designed Enzymes for Pharmaceutical Innovation", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1675971158, "tags": [ "Generative AI", "Synthetic Biology", "Biotech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/pando-bioscience", "api": "https://yc-oss.github.io/api/batches/winter-2023/pando-bioscience.json" }, { "id": 28794, "name": "Ohmic Biosciences", "slug": "ohmic-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5b68cb6a90af9c37176d63232ab7f6372925388d.png", "website": "https://ohmicbiosciences.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Pests and pathogens cost the world hundreds of billions of dollars every year. Existing technologies like agrochemicals are no longer working. Ohmic Biosciences uses protein engineering to design resistance genes for crops that are robust to pathogen evolution.", "one_liner": "Genetically engineering plants for disease resistance.", "team_size": 2, "industry": "Industrials", "subindustry": "Industrials -> Agriculture", "launched_at": 1689702500, "tags": [ "Synthetic Biology", "Biotech", "Climate", "Agriculture", "Genetic Engineering" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2023", "status": "Active", "industries": [ "Industrials", "Agriculture" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/ohmic-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2023/ohmic-biosciences.json" }, { "id": 28891, "name": "Numen", "slug": "numen", "former_names": [ "Cleancard" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/801ff758c035f5849acfdcd35329ec161bd30cef.png", "website": "https://www.numen.com", "all_locations": "San Francisco, CA, USA", "long_description": "", "one_liner": "Engineering a future without cancer deaths.", "team_size": 18, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1691571179, "tags": [ "Machine Learning", "Biotech", "Healthcare", "Diagnostics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2023", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/numen", "api": "https://yc-oss.github.io/api/batches/summer-2023/numen.json" }, { "id": 28923, "name": "Maven Bio", "slug": "maven-bio", "former_names": [ "RightPage" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4d8ec5197bc9e6a36464adaa019fa08dc09b5662.png", "website": "https://mavenbio.com", "all_locations": "Boston, MA, USA", "long_description": "Maven Bio is a 10-person seed-stage team in Boston building the market intelligence layer for life sciences AI. Three of the top 10 pharma companies are onboarded, and we have 20+ enterprise accounts across pharma, consulting, and investing. Customers report a 40% reduction in low-level analytical work.\r\n\r\nWe are growing fast and heading for a Series A. Our buyers are senior BD, CI, Strategy, and Investing leaders.", "one_liner": "The AI Platform for Life Sciences Intelligence", "team_size": 10, "industry": "B2B", "subindustry": "B2B", "launched_at": 1689099430, "tags": [ "Generative AI", "Biotech", "Healthcare", "Enterprise", "Healthcare IT" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2023", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/maven-bio", "api": "https://yc-oss.github.io/api/batches/summer-2023/maven-bio.json" }, { "id": 28967, "name": "MantleBio", "slug": "mantlebio", "former_names": [ "DryBox Bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/15716b62f7c6d475631f039d985c650683ee0837.png", "website": "https://www.mantlebio.com", "all_locations": "", "long_description": "Mantle brings modern data engineering to the lab to help scientists turn insights into world-changing breakthroughs.", "one_liner": "Transform scientific data into discoveries", "team_size": 7, "industry": "B2B", "subindustry": "B2B", "launched_at": 1689053097, "tags": [ "SaaS", "Biotech", "Data Science" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2023", "status": "Inactive", "industries": [ "B2B" ], "regions": [ "Unspecified" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/mantlebio", "api": "https://yc-oss.github.io/api/batches/summer-2023/mantlebio.json" }, { "id": 28974, "name": "Gleam", "slug": "gleam", "former_names": [ "gleam" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/cd818311eead953bafedec5b0c136092492541ea.png", "website": "https://joingleam.com", "all_locations": "San Francisco, CA, USA", "long_description": "Gleam automates data entry for clinical research sites.", "one_liner": "Automating Data Entry for Clinical Trials", "team_size": 4, "industry": "B2B", "subindustry": "B2B", "launched_at": 1690443767, "tags": [ "Artificial Intelligence", "Biotech", "Healthcare" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2023", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/gleam", "api": "https://yc-oss.github.io/api/batches/summer-2023/gleam.json" }, { "id": 29051, "name": "Nanograb", "slug": "nanograb", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9ae1f1866a70286591b56aa5fd2f81bdf18af255.png", "website": "https://nanograb.com", "all_locations": "San Francisco, CA, USA", "long_description": "Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale. ", "one_liner": "Deliver genes to any cell with AI", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1688618716, "tags": [ "AI-powered Drug Discovery", "Nanomedicine", "Biotech", "Drug Delivery", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2023", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/nanograb", "api": "https://yc-oss.github.io/api/batches/summer-2023/nanograb.json" }, { "id": 29305, "name": "SynsoryBio", "slug": "synsorybio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2b7538a15335c79e864ff7431e761c3feca0797.png", "website": "https://www.synsorybio.com/", "all_locations": "Boston, MA, USA", "long_description": "SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.", "one_liner": "\"If-then\" conditional logic for protein drugs", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1707422039, "tags": [ "Synthetic Biology", "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/synsorybio", "api": "https://yc-oss.github.io/api/batches/winter-2024/synsorybio.json" }, { "id": 29340, "name": "Tamarind Bio", "slug": "tamarind-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/201884765e11baf051338d72f6f2e7ead2bb1fa1.png", "website": "https://www.tamarind.bio", "all_locations": "San Francisco, CA, USA", "long_description": "Tamarind Bio is a website and API which allows scientists to use computational biology tools at scale using a simple interface. On Tamarind, scientists can use ML models like AlphaFold to design and simulate molecules by simply selecting inputs instead of or setting up a high performance computing environment or dealing with DevOps.\r\n\r\n\r\nTamarind is used by tens of thousands researchers in large pharma companies, top biotechs, and academic institutions.", "one_liner": "AI Inference Platform for Drug Discovery", "team_size": 20, "industry": "B2B", "subindustry": "B2B", "launched_at": 1702859345, "tags": [ "AI-powered Drug Discovery", "Artificial Intelligence", "SaaS", "B2B", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/tamarind-bio", "api": "https://yc-oss.github.io/api/batches/winter-2024/tamarind-bio.json" }, { "id": 29406, "name": "ACX", "slug": "acx", "former_names": [ "AcX Therapeutics", "AcX" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9bb37e7a5bced1e654bfc08df7f21868e28bd64c.png", "website": "https://www.acxtherapeutics.com/", "all_locations": "New York, NY, USA", "long_description": "ACX is developing a new standard for precision agriculture technologies by providing sustainable, eco-friendly alternatives to chemical pesticides. Our mission is to transform agriculture through sustainable biological crop protection that increases yields while safeguarding the environment, farmers, and consumers.\r\n", "one_liner": "Next-generation biocides for sustainable agriculture at scale", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1721937425, "tags": [ "Synthetic Biology", "Biotech", "Healthcare", "Agriculture", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/acx", "api": "https://yc-oss.github.io/api/batches/summer-2024/acx.json" }, { "id": 29412, "name": "Ligo Biosciences", "slug": "ligo-biosciences", "former_names": [ "Ligo", "Ligo Bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/bd381079ddb420940e9b57512009e6b5bc73e27a.png", "website": "https://www.ligo.bio", "all_locations": "San Francisco, CA, USA", "long_description": "We are building the next generation of deep-learning models for enzyme design to slash the cost of chemical manufacturing. The $6 trillion chemical industry is flawed: It produces 20% of industrial greenhouse gases, and is responsible for 15% of global energy usage. \r\n\r\nEnzymes offer a far more sustainable alternative to chemical synthesis and have already revolutionised how a select few chemicals are produced. The problem is each enzyme takes years of trial and error to develop. Our enzyme models learn the principles of catalysis, allowing us to design enzymes for each reaction, in days not years. \r\n", "one_liner": "Enzyme design models.", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1723173017, "tags": [ "Artificial Intelligence", "Deep Learning", "Synthetic Biology", "Biotech", "Climate" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/ligo-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2024/ligo-biosciences.json" }, { "id": 29429, "name": "Velorum Therapeutics", "slug": "velorum-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f201fcf7f4408f2acdedabe7f9bef2baabec8369.png", "website": "https://www.velorumtx.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Velorum Therapeutics is developing breakthrough medicines by unlocking the biology of heme.", "one_liner": "Breakthrough medicines unlocking the biology of heme", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1706719304, "tags": [ "Biotech", "Healthcare", "Therapeutics", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/velorum-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2024/velorum-therapeutics.json" }, { "id": 29470, "name": "Eris Biotech", "slug": "eris-biotech", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b16bbab6bd8003573ebc3410a08531b90c3427fd.png", "website": "http://www.erisbio.com", "all_locations": "Lehi, UT, USA", "long_description": "We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma. ", "one_liner": "Our drugs engage the immune system to fight tumors", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1706246904, "tags": [ "Biotech", "Therapeutics", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/eris-biotech", "api": "https://yc-oss.github.io/api/batches/winter-2024/eris-biotech.json" }, { "id": 29475, "name": "Evolvere BioSciences", "slug": "evolvere-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/dd3489b7e5a5f2d3f7cc49de65917a83134da0a3.png", "website": "https://www.evolverebiosciences.com/", "all_locations": "Oxford, England, United Kingdom", "long_description": "🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. \r\n\r\n☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. \r\n\r\n🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️.\r\n\r\nWe are a team of biochemists and evolutionary biologists who met at the University of Oxford. ", "one_liner": "Making Next-Generation Antibiotics that Outpace Bacterial Evolution", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1723833827, "tags": [ "AI-powered Drug Discovery", "Artificial Intelligence", "Biotech", "Therapeutics", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/evolvere-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2024/evolvere-biosciences.json" }, { "id": 29485, "name": "Granza Bio", "slug": "granza-bio", "former_names": [ "Zyme Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e4fe5f43800f16c0ca16303f58b955037e3f2bc1.png", "website": "https://www.granzabio.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity. ", "one_liner": "Building programmable therapeutics for the immune system", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1709082658, "tags": [ "Synthetic Biology", "Biotech", "Healthcare", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/granza-bio", "api": "https://yc-oss.github.io/api/batches/winter-2024/granza-bio.json" }, { "id": 29527, "name": "ParcelBio", "slug": "parcelbio", "former_names": [ "Parcel Therapuetics", "Parcel Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/74f762bd0f8856c1dbe4d716afa6585e44f03870.png", "website": "https://parcelbio.com/", "all_locations": "San Francisco, CA, USA", "long_description": "ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.", "one_liner": "Elevated mRNA for transformative medicines.", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1707343020, "tags": [ "Gene Therapy", "Synthetic Biology", "Biotech", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/parcelbio", "api": "https://yc-oss.github.io/api/batches/winter-2024/parcelbio.json" }, { "id": 29532, "name": "Ångström AI", "slug": "angstrom-ai", "former_names": [ "Angstrom AI" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d66ae246dae1ca35e8275f53019cac07d3259c99.png", "website": "https://www.angstrom-ai.com", "all_locations": "San Francisco, CA, USA", "long_description": "Angstrom AI builds GenAI-based molecular simulations to substitute wet lab experiments in the pre-clinical drug development pipeline. We are a team of 2 PhD's and 2 Professors from the University of Cambridge who decided to start a company together after we realised how to combine breakthoughs in our research in quantum-accurate models of physics and generative AI models.\r\n\r\nOur Biotech/Pharma clients can verify the efficacy and safety of new drug candidates using our computer simulations, which match the accuracy of wet lab experiments, but are over 100x faster. We achieve this accuracy by constraining our genAI-based simulations to obey the laws of physics, avoiding the hallucinations seen in other GenAI technologies.\r\n\r\nSince joining YC, Angstrom AI has developed the first physically accurate gen-AI based simulation of multiple molecules interacting. We have published the first molecule water solubility results with accuracy within the error range of wet lab experiments. We have also kicked-off a 150K pilot project with a pharma company to apply our tech to estimating solubility in their drug development pipeline.", "one_liner": "Gen AI molecular simulations that reproduce wetlab results", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1719350589, "tags": [ "AI-powered Drug Discovery", "Artificial Intelligence", "Biotech", "Drug discovery", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/angstrom-ai", "api": "https://yc-oss.github.io/api/batches/summer-2024/angstrom-ai.json" }, { "id": 29573, "name": "Undermind", "slug": "undermind", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2e44c4453098a5caed0988fdf2dff5b898cdcac4.png", "website": "https://www.undermind.ai", "all_locations": "San Francisco, CA, USA", "long_description": "At Undermind, we're building a search engine that can handle extremely complex questions. It’s geared at experts, like research scientists and doctors, who need to find very specific resources to solve high-stakes problems. \r\n\r\nWe’ve rebuilt search from the ground up to address this. Our new approach employs high-quality LLMs to adaptively explore a database, mimicking how a human researcher carefully discovers information. This approach dramatically outperforms (by 10-50x) traditional keyword search and other modern AI-based retrieval methods.\r\n\r\nOur first target users are the 50 million researchers searching for scientific literature on PubMed and Google Scholar every month. We’ve have paying users across fields like medicine, ML, biotech, finance, and more.", "one_liner": "An AI agent for scientific research", "team_size": null, "industry": "B2B", "subindustry": "B2B", "launched_at": 1718632251, "tags": [ "Machine Learning", "Biotech", "Search", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/undermind", "api": "https://yc-oss.github.io/api/batches/summer-2024/undermind.json" }, { "id": 29694, "name": "AminoAnalytica", "slug": "aminoanalytica", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f7d5463656052d09bd1bc697531992af867d844c.png", "website": "https://www.aminoanalytica.com", "all_locations": "London, United Kingdom", "long_description": "We design point-of-care molecular diagnostics for emerging biological threats - in weeks, not 12+ months.", "one_liner": "The AI scientist for always-on biodefense", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1715962434, "tags": [ "Nanosensors", "Synthetic Biology", "Biotech", "Diagnostics", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/aminoanalytica", "api": "https://yc-oss.github.io/api/batches/summer-2024/aminoanalytica.json" }, { "id": 29713, "name": "Anthrogen", "slug": "anthrogen", "former_names": [ "Arctic Capture" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b82e4439479abc4af4baa257faf13f88240781b4.png", "website": "https://anthrogen.com", "all_locations": "San Francisco, CA, USA", "long_description": "Proteins power everything from the cells in your body to creating materials you rely on every day—but until now, we’ve been forced to discover their functions by trial and error. Designing a new therapeutic can take decades and billions of dollars, and even our best industrial catalysts work at a snail’s pace compared to their theoretical optimums.\r\n\r\nAnthrogen is changing that. By training massive AI foundation models on protein sequences and structures, we’ve unlocked the ability to generate—on demand—completely novel molecular machines with atomic-level precision. Simply describe the function you need, and our platform imagines the peptide or protein that will deliver it.\r\n\r\nWe're building models to speed up billions of years of evolution into the span of an afternoon's worth of compute.\r\n\r\nThe result? New-to-nature therapies, ultra-efficient catalysts for sustainable manufacturing, and a whole new frontier of molecular innovation—designed as precisely as any cutting-edge aircraft or microchip.", "one_liner": "We're training the next generation of protein foundation models.", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1717790065, "tags": [ "Artificial Intelligence", "Deep Learning", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/anthrogen", "api": "https://yc-oss.github.io/api/batches/summer-2024/anthrogen.json" }, { "id": 29714, "name": "Kopra Bio", "slug": "kopra-bio", "former_names": [ "GlioTx" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/acdb0c2a3124d9e5717a63d0231af9b6f7447919.png", "website": "https://kopra.bio", "all_locations": "San Francisco, CA, USA", "long_description": "Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.", "one_liner": "Genetically engineered viruses that teach your immune system to kill…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1724130421, "tags": [ "Gene Therapy", "Synthetic Biology", "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/kopra-bio", "api": "https://yc-oss.github.io/api/batches/summer-2024/kopra-bio.json" }, { "id": 29733, "name": "1849 bio", "slug": "1849-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6a17250c337f8e98ac79079d08da2abffb3b3b6b.png", "website": "https://www.1849.bio", "all_locations": "San Francisco, CA, USA", "long_description": "1849 bio designs microbes enabling cheap metal extraction allowing miners to unlock value from low quality copper and gold ores. Surprisingly, the mining industry is one of the largest scale users of biotech in the world with biomining processes accounting for ~1% of global copper production. Biomining is ultra-low cost, running around ~$1/ton of ore vs ~$7/ton for conventional processes. \r\n\r\nUnfortunately, while biomining is cheap, it can’t be applied to over 80% of copper ores, leaving vast resources without profitable extraction methods. An estimated ~$800B of copper sit today in waste materials and stockpiles with negative unit economics.\r\n\r\nWhile a great deal of effort has been spent on optimizing microbial metal extraction processes, very little effort has been spent on optimizing the microbes themselves. \r\n\r\nTo change that, we’re creating new biotech tools and platforms applied directly to the types of biology most relevant to miners. This enables us to develop new microbes and tackle some of the most difficult problems in biomining, unlocking billions in value from unprofitable resources while being more environmentally friendly than conventional processes.\r\n\r\nWe’re world class microbial engineers. We met while doing our PhDs in synthetic biology, where we spent our time applying and developing the most advanced bioengineering technologies to engineer living cells. ", "one_liner": "Engineering microbes for miners to unlock billions in trapped metal", "team_size": 3, "industry": "Industrials", "subindustry": "Industrials", "launched_at": 1720558135, "tags": [ "Hard Tech", "Synthetic Biology", "Biotech", "Climate", "Mining" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Industrials" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/1849-bio", "api": "https://yc-oss.github.io/api/batches/summer-2024/1849-bio.json" }, { "id": 29749, "name": "Biocartesian", "slug": "biocartesian", "former_names": [ "coordna bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/829faf276e5fc759cb0c8e72860cd6cdab552050.png", "website": "https://www.biocartesian.com", "all_locations": "San Francisco, CA, USA", "long_description": "Finding new cures requires seeing what and where the abnormal molecules are in a diseased tissue, but current tools see less than 1% of those molecules. Biocartesian combines microscopy and new chemistries to see 50X more, offering unprecedented insights into disease biology and new therapies.", "one_liner": "Converting biology into digital molecular maps", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1724915415, "tags": [ "Hard Tech", "B2B", "Biotech", "Diagnostics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/biocartesian", "api": "https://yc-oss.github.io/api/batches/summer-2024/biocartesian.json" }, { "id": 29794, "name": "Baseline AI", "slug": "baseline-ai", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3a2cd9231d352195b9c81d40c7f7df4295e580f3.png", "website": "https://www.baselinetrials.com/", "all_locations": "San Francisco, CA, USA", "long_description": "The main document in a clinical trial is the study protocol. At large companies, floors of people use the protocol to create the study data collection forms, clinical database design, error checks, analysis code, and data transformation mappings. We use AI to automate the process of creating everything from the protocol, saving not only spend on headcount but also months of time which can translate to up to $27M in direct costs + lost revenue saved for a single phase 3 trial. ", "one_liner": "AI document creation and data management for clinical trials", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare IT", "launched_at": 1724199477, "tags": [ "Artificial Intelligence", "SaaS", "Health Tech", "B2B", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Healthcare IT" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/baseline-ai", "api": "https://yc-oss.github.io/api/batches/summer-2024/baseline-ai.json" }, { "id": 29986, "name": "Exin Therapeutics", "slug": "exin-therapeutics", "former_names": [ "EI Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/61d9c34b51f9b98cbfdb92bc0014e3569c29b36c.png", "website": "https://www.exintherapeutics.com/", "all_locations": "San Francisco, CA, USA", "long_description": "We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house.\r\n\r\nWe are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL.\r\n\r\nIn 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding. \r\n", "one_liner": "AI drug discovery platform for neurotherapeutics", "team_size": 9, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1736839155, "tags": [ "Neurotechnology", "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2025", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/exin-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2025/exin-therapeutics.json" }, { "id": 29988, "name": "Delineate", "slug": "delineate", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/157ef705774b4b91cf62de3244f82d80101e257a.png", "website": "https://delineate.pro/", "all_locations": "Boston, MA, USA; Remote", "long_description": "Delineate is building AI agents to design better clinical trials faster.\r\n\r\nThis is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential.\r\n\r\nWe process existing clinical trial research into specialized datasets saving scientists months of effort.\r\n\r\nDelineate is working with two of the largest pharmaceutical companies. With one of our customers, we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.", "one_liner": "Agents for Accelerated Clinical Trial Design", "team_size": 20, "industry": "B2B", "subindustry": "B2B -> Engineering, Product and Design", "launched_at": 1739310156, "tags": [ "SaaS", "Biotech", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2025", "status": "Active", "industries": [ "B2B", "Engineering, Product and Design" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/delineate", "api": "https://yc-oss.github.io/api/batches/winter-2025/delineate.json" }, { "id": 30039, "name": "Raycaster", "slug": "raycaster", "former_names": [ "Atlas" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/8e3854e63389e5cabd44e4b6563fefc3bd539147.png", "website": "https://raycaster.ai", "all_locations": "New York, NY, USA", "long_description": "Raycaster is an AI document workspace - think Cursor for regulated content, starting with life sciences teams to draft, edit, and review submissions much faster.", "one_liner": "AI for life sciences documents", "team_size": 3, "industry": "B2B", "subindustry": "B2B -> Productivity", "launched_at": 1729820914, "tags": [ "Artificial Intelligence", "SaaS", "Biotech", "Enterprise Software" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Fall 2024", "status": "Active", "industries": [ "B2B", "Productivity" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/raycaster", "api": "https://yc-oss.github.io/api/batches/fall-2024/raycaster.json" }, { "id": 30049, "name": "Reticular", "slug": "reticular", "former_names": [ "Advocate" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/077de5cdaa18c1c7dd719188ef7fdeadce5020aa.png", "website": "https://reticular.com", "all_locations": "San Francisco, CA, USA", "long_description": "Reticular is scaling polygenic prediction for embryo selection, helping IVF couples plan their families today while building a platform to unlock cures for complex heritable diseases long-term.\r\n\r\nJohn competed Biology Olympiads before spending 4 years at MIT publishing ML/bio research in NeurIPS and Nature. We believe biological models encode far more information than anyone is currently using - our goal is to unlock this potential.", "one_liner": "Scaling Genomic AI for Embryo Selection", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Consumer Health and Wellness", "launched_at": 1731023720, "tags": [ "Generative AI", "Consumer Health Services", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Fall 2024", "status": "Active", "industries": [ "Healthcare", "Consumer Health and Wellness" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/reticular", "api": "https://yc-oss.github.io/api/batches/fall-2024/reticular.json" }, { "id": 30399, "name": "Frekil", "slug": "frekil", "former_names": [ "Notate" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/1e885d9503dffbb01e24f5bd3a78965979764099.png", "website": "https://www.frekil.com", "all_locations": "Bengaluru, India", "long_description": "Today, it takes months to understand how drugs perform in the real world, delaying safety insights and leaving patients exposed to unknown risks and benefits for far too long. Frekil turns that months-long process into minutes, with full auditability and scientific rigor.\r\n\r\nFrekil accelerates real world evidence (RWE) generation for life sciences companies on their own clinical data from months to minutes. It connects to fragmented clinical data (EHR, Claims, etc.) and lets teams run end-to-end studies from study design, cohort extraction to SAP, statistical analysis, and final reports.", "one_liner": "RWE Generation in minutes", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1744440110, "tags": [ "Artificial Intelligence", "Health Tech", "B2B", "Biotech", "Healthcare" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Spring 2025", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "India", "South Asia" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/frekil", "api": "https://yc-oss.github.io/api/batches/spring-2025/frekil.json" }, { "id": 30421, "name": "Synthio Labs", "slug": "synthio-labs", "former_names": [ "SynthioLabs" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9098a7fb6ce97083cb31b3aea4f58a15ab42e106.png", "website": "https://synthiolabs.com/", "all_locations": "San Francisco, CA, USA", "long_description": "The intelligence layer behind modern life sciences engagement, enabling compliant, continuous conversations across HCPs, patients, and field teams", "one_liner": "Agentic AI platform for Pharma GTM teams", "team_size": 29, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1744430433, "tags": [ "Artificial Intelligence", "Biotech", "Healthcare", "Enterprise" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Spring 2025", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/synthio-labs", "api": "https://yc-oss.github.io/api/batches/spring-2025/synthio-labs.json" }, { "id": 30516, "name": "Bramante", "slug": "bramante", "former_names": [ "LabKick Corporation", "LabKick", "Bramante Biologics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d13627b06670d3337bda071d8e7bccb8d6728ffd.png", "website": "https://www.bramantebio.com", "all_locations": "Cambridge, MA, USA", "long_description": "We manufacturing instruments and reagents that are purpose built for AI, automated labs, and personalized medicines.", "one_liner": "Life sciences instrument and reagent manufacturing", "team_size": 2, "industry": "Industrials", "subindustry": "Industrials -> Manufacturing and Robotics", "launched_at": 1747846039, "tags": [ "Biotech", "Manufacturing", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Spring 2025", "status": "Active", "industries": [ "Industrials", "Manufacturing and Robotics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/bramante", "api": "https://yc-oss.github.io/api/batches/spring-2025/bramante.json" }, { "id": 30671, "name": "Panoptive", "slug": "panoptive", "former_names": [ "AgentHub" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e968a9edc53bbf932ccbe0585917fe2029077b90.png", "website": "https://www.panoptive.com", "all_locations": "San Francisco, CA, USA", "long_description": "We turn unstructured monitoring data - monitoring visit reports, EDC data - into structured deviation, safety, and quality findings for human review. Panoptive generates an audit-ready oversight trail as a natural byproduct. \r\n\r\nThe platform aggregates findings and identifies systemic patterns across sites and subjects before they compound, and tracks every finding through decision, follow-up, and resolution.", "one_liner": "The continuous oversight engine for clinical trials", "team_size": 2, "industry": "B2B", "subindustry": "B2B", "launched_at": 1753389326, "tags": [ "B2B", "Biotech", "Infrastructure", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2025", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/panoptive", "api": "https://yc-oss.github.io/api/batches/summer-2025/panoptive.json" }, { "id": 30702, "name": "TwentyTwo", "slug": "twentytwo", "former_names": [ "Muon", "Mohi" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5be6b2304553a4bca9bfa1f2953ae02638a8d430.png", "website": "https://twentytwo.bio/", "all_locations": "New York, NY, USA", "long_description": "AI is making biology easy to engineer. Life-saving drugs and therapies are accelerating, but so is the ability for bad actors to create a pandemic. TwentyTwo is working on the defensive stack to prevent the next pandemic.", "one_liner": "AI infrastructure for biosecurity", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1753262535, "tags": [ "Artificial Intelligence", "Synthetic Biology", "Biotech", "Compliance", "Security" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2025", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/twentytwo", "api": "https://yc-oss.github.io/api/batches/summer-2025/twentytwo.json" }, { "id": 30747, "name": "Convexia", "slug": "convexia", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c68bf871c0fe363c6048343df283d9282ab990f4.png", "website": "https://convexia.bio", "all_locations": "San Francisco, CA, USA", "long_description": "An AI-maximalist pharma platform. We use agents to buy drugs, run clinical trials, and sell for a profit. 10x faster and 20x leaner than incumbents.\r\n\r\nSourcing Agent: Mines public/private databases and unstructured global data to surface overlooked preclinical candidates.\r\nScientific Agent: Runs comp bio models (ESM-3, RFdiffusion, Boltz-2, AlphaFold) to assess safety and efficacy in silico.\r\nCommercial Agent: Analyzes FDA incentives, pricing dynamics, TAM, competitive landscape, and payer alignment.\r\nClinical Agent: Runs digital twin simulations, evaluates CRO/CMC risk, and builds trial plans to Phase 1.\r\nPoS Agent: Evaluates the most critical factors that impact the likelihood of clinical trial success. \r\n\r\nBuilt by 2 Stanford CS students who have built 3 startups together before. ", "one_liner": "The world's first AI-maximalist pharma company", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1752301183, "tags": [ "AI-powered Drug Discovery", "Biotech", "Drug Delivery" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2025", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": true, "url": "https://www.ycombinator.com/companies/convexia", "api": "https://yc-oss.github.io/api/batches/summer-2025/convexia.json" }, { "id": 30856, "name": "Scoop", "slug": "scoop", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/70fc9c8245a9de2b245841faf07e0530dd3f51a1.png", "website": "https://scooplabs.ai", "all_locations": "San Francisco, CA, USA", "long_description": "We’re building AI agents that speed up drug trials by automating the manual consolidation and document prep required for every IND submission. Today, biotechs spend months stitching together reports from contractors and internal teams just to file and get to their first-in-human trial.", "one_liner": "Automating regulatory submissions for life sciences", "team_size": 2, "industry": "B2B", "subindustry": "B2B", "launched_at": 1762725446, "tags": [ "Artificial Intelligence", "B2B", "Biotech", "Compliance", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Fall 2025", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/scoop", "api": "https://yc-oss.github.io/api/batches/fall-2025/scoop.json" }, { "id": 30925, "name": "Play Health", "slug": "play-health", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/757bc1cfa9101d42dcc0cd813d53a54fd8552a06.png", "website": "http://playhealth.com", "all_locations": "Boulder, CO, USA", "long_description": "Play Health is building a perimenopause care platform to provide women and their providers with the tools they need to relieve symptoms fast. It is led by technical, second-time, YC-backed founders Andrea Mazzocchi, PhD and Ian Miller, with an exit and a unicorn between them.\r\n\r\nOver 30 million women in the U.S. are experiencing perimenopause symptoms, spending an estimated $15B+ annually on symptom management. Despite this most only receive generic solutions and struggle to find effective symptom relief.\r\n\r\nWe're bringing evidence-based perimenopause care to women through partnerships with medical practices and employer and health benefits programs. Our platform integrates personalized symptom, medication, and lifestyle data to generate AI-powered insights and clinical protocols, enabling providers to deliver specialized care.\r\n\r\nEvery clinical interaction enriches our longitudinal dataset allowing us to create better outcomes for patients, deeper insights for providers, and expand into women’s health broadly. This also enables us to partner with pharma and biotech companies developing therapeutics and diagnostics for women's health.", "one_liner": "Perimenopause Care Platform", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1760457684, "tags": [ "Biometrics", "Biotech", "Digital Health", "Health & Wellness", "Women's Health" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Fall 2025", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/play-health", "api": "https://yc-oss.github.io/api/batches/fall-2025/play-health.json" }, { "id": 30937, "name": "Anto Biosciences", "slug": "anto-biosciences", "former_names": [ "Anto" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/83f56c369ac0fb5e70438516e774b8603717940a.png", "website": "https://www.anto.bio/", "all_locations": "San Francisco, CA, USA", "long_description": "Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving the hidden root cause of most drug failures. \r\n\r\nFounded by Arvid (Broad Institute of MIT and Harvard; Nature-published researcher who pioneered quality-aware, goal-directed sparsification) and David (Harvard Medical School Gastroenterology, J&J), second-time founders who published the breakthrough at leading machine learning AI conferences and Nature. ", "one_liner": "A Foundation Model for Microbial Communities.", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1761948352, "tags": [ "Artificial Intelligence", "Generative AI", "Biotech", "Genomics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Fall 2025", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/anto-biosciences", "api": "https://yc-oss.github.io/api/batches/fall-2025/anto-biosciences.json" }, { "id": 31098, "name": "10x Science", "slug": "10x-science", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/80a81e39e735a3e350222fa5fd72596c97653b0a.png", "website": "https://10xscience.com", "all_locations": "San Francisco, CA, USA", "long_description": "10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development.\r\n\r\nAI-powered drug discovery is flooding the pipeline with new candidates faster than ever. But before any of them can advance to the clinic, scientists must deeply characterize the protein therapeutic to understand whether it will work. Today, that process takes months of manual, error-prone analysis that cannot keep pace with discovery. Our AI-native platform automates it, giving drug developers the confidence to advance the right candidates and stop the wrong ones early.\r\n\r\nWe have strong commercial traction with enterprise pharma customers. Our founding team built the field of next-generation protein characterization out of Carolyn Bertozzi's Nobel laureate lab at Stanford. Collectively, we have 18+ years of collective domain expertise, 47+ scientific publications, and a 2x YC Founder. We move at the highest velocity and are positioned to lead the next generation of modern AI development in the life sciences. ", "one_liner": "The AI-native platform for next-generation protein characterization.", "team_size": 3, "industry": "B2B", "subindustry": "B2B", "launched_at": 1768312668, "tags": [ "SaaS", "B2B", "Biotech", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2026", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/10x-science", "api": "https://yc-oss.github.io/api/batches/winter-2026/10x-science.json" }, { "id": 31441, "name": "Infera", "slug": "infera", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e31e68f847b8067b4a5a541fed968e4b0739a6c4.png", "website": "https://www.infera.bio", "all_locations": "San Francisco, CA, USA", "long_description": "Describe an experiment in plain English, and Infera turns it into a validated, instrument-ready run across the equipment your lab already uses. Infera handles the protocol logic, vendor-specific scripts, data, inventory, and institutional knowledge in one system. An AI-native compiler for the lab: one system from intent to execution.", "one_liner": "Control lab instruments with natural language.", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1779916747, "tags": [ "SaaS", "B2B", "Biotech", "Automation", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Spring 2026", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/infera", "api": "https://yc-oss.github.io/api/batches/spring-2026/infera.json" }, { "id": 32521, "name": "Molagri", "slug": "molagri", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/73c2cb671f399e3f094f4caf701a63e06155fc4f.png", "website": "https://molagri.com", "all_locations": "Toronto, ON, Canada", "long_description": "Molagri develops safer, more effective pesticides for agriculture.\r\n\r\nWe design biopesticides that hit a precise molecular target unique to pest insects, knocking out pests while sparing pollinators, beneficial insects, and the wider ecosystem. By modeling how pests are likely to evolve, we stay a step ahead of resistance, keeping our products effective against the pests of today and tomorrow. The higher efficacy and biobased production will also contribute to emissions reductions in both manufacturing and field use.\r\n\r\nOur founders are PhD lab mates from the University of Toronto who have worked together for six years and published in Nature Communications and Nature Microbiology. \r\n", "one_liner": "Biopesticides that are safe for humans and bees.", "team_size": 4, "industry": "Industrials", "subindustry": "Industrials -> Agriculture", "launched_at": 1782770010, "tags": [ "Synthetic Biology", "Biotech", "Sustainability", "Climate", "Agriculture" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2026", "status": "Active", "industries": [ "Industrials", "Agriculture" ], "regions": [ "Canada", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/molagri", "api": "https://yc-oss.github.io/api/batches/summer-2026/molagri.json" } ]